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  ABSTRACT 
Fructose-1,6-bisphosphatase (FBPase) is a critical regulatory enzyme in gluconeogenesis.  
In mammals, the enzyme is subject to metabolic regulation; the hormones insulin and glucagon 
reciprocally regulate the enzyme in the liver through the controlled production and degradation of 
the inhibitor fructose-2,6-bisphosphate (Fru-2,6-P2) and hence control hepatic glucose 
production.  FBPase is nearly ubiquitous in living organisms and in the bacterium Escherichia 
coli, the homologous enzyme is imperative for growth on gluconeogenic substrates.  How does 
this organism regulate FBPase without the use of exogenous hormones or Fru-2,6-P2?  
Investigations reported herein describe high resolution crystal structures of the enzyme from E. 
coli which have revealed the existence of both novel allosteric activation and inhibition sites for 
metabolites in the glycolytic/gluconeogenic pathway, transforming the accepted schemes of 
regulation of glycolysis and gluconeogenesis in bacteria.  Metabolites upstream of FBPase 
(phosphoenolpyruvate, citrate, and others) activate the enzyme while downstream products 
(glucose 6-phosphate) inhibit the enzyme in classical feed-forward activation and feed-back 
inhibition schemes.  Additionally, both types of effectors leverage their impact by altering the 
affinity of the enzyme for the ubiquitously present inhibitor AMP in a manner analogous to the 
effect of Fru-2,6-P2 on the mammalian enzyme.  A complex regulatory scheme for bacterial 
FBPase is described herein which also illustrates how distinct regulatory mechanisms can co-
evolve to utilize the same protein scaffold.  Further investigations revealed changes in the 
mammalian enzyme in response to physiological effectors, which answer questions that have 
been unresolved for 25 years and enrich the current understanding of mammalian metabolic 
regulation.  These observations have direct relevance to human health, specifically in the 
treatment of Type 2 diabetes.  Future investigations may lead to the development of novel 
inhibitors toward mammalian FBPase which can relieve diabetic hyperglycemia.     
1 
CHAPTER I.  INTRODUCTION 
Fructose-1,6-bisphosphatase (D-fructose-1,6-bisphosphate 1-phosphohydrolase, EC 
3.1.3.11; FBPase)1 is an enzyme in the gluconeogenic pathway that catalyzes the formation 
of fructose 6-phosphate (Fru-6-P) and inorganic phosphate (Pi) by the hydrolysis of fructose 
1,6-bisphosphate (Fru-1,6-P2) (for reviews see 1, 2).  Two subsequent reactions convert Fru-
6-P to glucose (2).  Fructose-2,6-bisphosphate (Fru-2,6-P2), the concentration of which is 
under hormonal control in mammals, in principle determines the flux through the 
gluconeogenic pathway (Figure 1) (3).  In addition to activating the opposing glycolytic 
enzyme fructose-6-phosphate-1-kinase (PFK), Fru-2,6-P2 and adenosine 5´-monophosphate 
(AMP) inhibit mammalian FBPases synergistically, the former binding to the active site and 
the latter binding cooperatively to an allosteric site 28Å away (Figure 2) (3-6).  As a 
consequence of AMP/Fru-2,6-P2 synergy, elevated concentrations of Fru-2,6-P2 enhance 
AMP inhibition by up to 10-fold (5). 
Mammalian FBPases are homotetramers, each subunit having an active site (binding 
sites for Fru-1,6-P2 and three divalent metal cations) and a distinct AMP binding domain (7-
9).  Until recently, structures of FBPase belonged to one of two quaternary states (Figure 2) 
called R (inhibitors absent) and T (AMP-ligated) (9-11).  Recent investigations have 
identified IT- and IR- states, which are intermediate between canonical R- and T- states (12-
14).  The intermediate states are favored by specific mutants of FBPase under specific 
conditions of ligation (12-14). 
The structural mechanisms by which AMP and Fru-2,6-P2 inhibit porcine FBPase 
have been previously investigated and are, for the most part, well understood.  A dynamic  
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Figure 1.  Metabolite regulation of Glycolysis and gluconeogenesis in mammals.  Two 
allosteric enzymes, FBPase and fructose-6-phosphate-1-kinase (PFK), define a futile cycle at 
the expense of ATP.  The enzymes are reciprocally regulated: AMP and Fru-2,6-P2 inhibit 
FBPase while activating PFK, resulting in decreased glucose production and increased 
glycolytic flux. 
 
 
 
 
 3 
   
 
 
 
 
 
 
 
Figure 2: Mammalian FBPase homotetramer undergoing the global conformational 
change induced by AMP binding or release.  Subunits are labeled C1-C4 by convention.  
AMP induces a quaternary change from the R-state to the T-state which differ by a rotation 
of ‘top’ (C1-C2) and ‘bottom’ (C2-C3) dimers by 15o about a molecular symmetry axis as 
shown.   
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loop (residues 52-72 in the porcine enzyme) associates with the active site cleft of the same 
subunit, forming a binding site for an essential third metal cation (15).   
When the enzyme is in its active form (R-state), the dynamic loop can be in at least 
two conformations, disordered and engaged (15, 16).  The ability of the loop to switch 
between these two conformations is presumably necessary for catalysis and product release 
(16).  In the presence of AMP, the enzyme makes a transition to an inactive T-state and the 
dynamic loop is trapped in a disengaged conformation (Figure 3), preventing the formation 
of metal site 3 (14-16).  The binding site for Fru-2,6-P2, an analog of Fru-1,6-P2, was 
unsettled for some time, being either the active site or a distinct allosteric effector site (1, 17, 
18).  Crystal structures revealed the former, supporting observations of competition between 
Fru-2,6-P2 and Fru-1,6-P2 for the active site (19, 20).  In mammals, this is not the only effect 
of Fru-2,6-P2; its presence at inhibitory levels increases the sensitivity of mammalian 
FBPases to AMP and vice versa (5).  Several models explain this phenomenon.  Fluorescence 
experiments using a Tyr57→Trp mutation as a reporter group to detect the conformation of 
the dynamic loop have revealed that in the presence of Mg2+, Fru-2,6-P2 also displaces the 
loop, and hence inhibitory synergism could arise from the mutual stabilization of similar loop 
conformations (21).  Others have suggested that Fru-2,6-P2 may induce a global 
conformational change similar to the R to T transition induced by AMP (22).  The 
observations of intermediate (I-like) states of FBPase further support the theory that 
synergism may also arise from the stabilization of similar quaternary states of the enzyme 
(12-14).  Exactly how Fru-2,6-P2 is able to prevent the engaged conformation of the loop or 
stabilize an I-like state is still poorly understood. 
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Figure 3.  Engaged and disengaged conformations of the dynamic loop.  In the R-state, 
with no AMP bound, the dynamic loop (residues 52-72) takes on an ‘engaged’ conformation 
(right), associating with the active site and organizing metal site 3.  In the T-state, AMP-
bound, the loop is trapped away from the active site in the ‘disengaged’ conformation (left), 
associated with other subunits.  
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With few exceptions, FBPase is a ubiquitously expressed enzyme, found in nearly all 
organisms (2) and, to some degree, in nearly all tissues (23).  In one protozoan, the parasite 
Plasmodium falciparum responsible for malaria, the gene for FBPase is absent, along with  
other genes for enzymes in the gluconeogenic pathway (24).  Presumably, P. falciparum has 
no need for gluconeogenesis due to an ample supply of sugars from its host organism (24).   
Although P. falciparum is not likely unique, it is an exception to the general rule.  In 
the enteric bacterium Escherichia coli, the most likely role of FBPase is the production of 
five-carbon skeletons as precursors of nucleotides and polysaccharides (25, 26).  Deletion of 
the fbp gene, which encodes FBPase, creates strains which are indistinguishable from wild 
type when grown on glucose or other hexoses, but cannot grow on gluconeogenic substrates 
(25). 
Prokaryotic FBPases have been classified based on primary sequence homology (27).  
Currently there are five non-homologous FBPase types known in prokaryotes; Types I-III are 
found primarily in Bacteria, while Type IV is found in Archaea and type V in thermophilic 
prokaryotes from both domains (28).  All eukaryotic FBPases are homologous to prokaryotic 
Type I enzymes and due to the relatively high sequence identity (usually 30-40%), probably 
have similar overall folds.  Crystal structures have been deposited in the Protein Data Bank 
for Archaea Types IV and V, and for mammalian and chloroplast FBPases, but no structure 
of FBPase from any organism of the domain Bacteria is available. 
FBPase and PFK define a futile cycle with a net hydrolysis of ATP (Figure 1) (6).  
Hence, the coordinated regulation of these enzymes would be advantageous for any 
organism.  FBPase is a constitutive enzyme in E. coli; however futile cycling is minimal 
under both glycolytic (29) and gluconeogenic (30) conditions, suggesting a mechanism of 
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strict metabolic control at the enzyme level (25).  Despite this, little is known about the 
dynamic regulation of the primary FBPase in E. coli.  Previous investigations have reported 
that AMP is a potent inhibitor (26, 31-33).  While Fru-2,6-P2 inhibits the enzyme 
competitively (32, 33), this inhibition is not synergistic with AMP in E. coli (32). 
Additionally, Fru-2,6-P2 is not produced in E. coli, making AMP the only known 
physiological inhibitor (34, 35) .  Despite this, dynamic regulation by AMP is an unsatisfying 
hypothesis for metabolic regulation, as AMP levels remain relatively constant under both 
gluconeogenic and glycolytic conditions (36). 
Two other effectors of FBPase activity have been explored.  Babul et al. (31) have 
suggested that phosphoenolpyruvate (PEP) may be a physiological activator of the enzyme 
due to its ability to block AMP inhibition (31).  PEP levels in E. coli fluctuate more than 10-
fold between glycolytic and gluconeogenic growth conditions (37) and PEP is an inhibitor of 
the primary PFK in E. coli (38), and an activator of FBPases in several other prokaryotic 
organisms (27, 39-41).  Despite these observations, no structural or kinetic mechanism for 
any effector other than AMP has been suggested for E. coli FBPase.  Glucose 6-phosphate 
(Glc-6-P) also inhibits E. coli FBPase in a crude cell lysate; however, because the 
concentrations required for inhibition in that experiment were well above the known 
physiological range, no physiological significance has been attributed to Glc-6-P inhibition 
(42).   
Investigations of FBPase figure most prominently in some strategies to treat diabetes.  
Due to the increasing prevalence of Type II diabetes, and the implication that over-activity in 
gluconeogenesis is a primary cause of hyperglycemia associated with the disorder (43), 
mammalian FBPase has become a target for several pharmaceutical companies in the 
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development of anti-diabetic drugs (12, 44, 45).  Investigations have resulted in the 
development of several novel inhibitors (12, 44), and in one case, detailed knowledge of 
structure and mechanism of inhibition resulted in the rational design of a potential drug (45).  
This FBPase-specific inhibitor is capable of reducing hyperglycemia in diabetic rats (46).  It 
is evident that investigations of this system have the potential to positively impact human 
health; however much is still unknown about the mechanisms of regulation of mammalian 
FBPase.  An important property of mammalian FBPase, synergism in Fru-2,6-P2/AMP 
inhibition, however, is not understood in terms of a specific molecular mechanism.  
Moreover, no mutant construct of a mammalian FBPase has been reported that lacks 
synergism in Fru-2,6-P2/AMP inhibition without significant disruption of function. The 
investigation of E. coli FBPase, and its use as a model system, may aid in understanding the 
regulation of the mammalian system in this regard.  Fru-2,6-P2 and AMP individually are 
potent inhibitors of E. coli FBPase, but exhibit no synergism (32).  Because of its high 
sequence identity to the mammalian enzyme (41%) and identical overall fold, E. coli FBPase 
can be viewed as a functional mammalian system without Fru-2,6-P2/AMP synergism.  
Comparative analysis of E. coli and mammalian enzymes could reveal the molecular basis of 
synergism in the mammalian system. 
 
Thesis Organization 
This thesis contains six chapters.  A literature review with general information on 
fructose-1,6-bisphosphatase (FBPase) is contained in Chapter I.  Chapter II is a paper that has 
been published in The Journal of Biological Chemistry.  Recombinant E. coli FBPase was 
expressed and purified to homogeneity, and the first crystal structure of the enzyme 
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determined at high resolution.  The structure revealed a novel allosteric activation site at the 
interface between C1-C2 and C3-C4 dimers.  A plausible mechanism for regulation by 
phosphoenolpyruvate (PEP) and AMP is presented and the potential conservation of this new 
allosteric site in bacteria is suggested. 
Chapter III is also a paper which is published in the Journal of Biological Chemistry, 
describing the activation of E. coli FBPase by several intermediates in the glycolytic/ 
gluconeogenic pathway and the TCA cycle.  Structures of activated E. coli FBPase with 
bound physiological activators (phosphoenolpyruvate or citrate) are described, with emphasis 
placed on the observation that the quaternary state of the activated bacterial enzyme is 
identical to that of the active mammalian enzyme, implying conservation in evolution.  New 
evidence and an expanded survey of FBPase protein sequences revealed that the anion 
activation site is conserved across phylogenetic lines in heterotrophic bacteria.  The potential 
reasons for such conservation are discussed.   
The discovery of a mechanism of allosteric activation in E. coli FBPase raised new 
questions regarding the way in which FBPase may be inactivated in response to sudden 
glucose uptake, to avoid futile cycling in the bacterium and allow efficient utilization of the 
preferred substrate glucose.  Glucose 6-phosphate was determined to be an allosteric 
inhibitor of E. coli FBPase on the basis of structural and kinetic evidence, described in 
Chapter IV.  Glc-6-P binds to E. coli FBPase in a novel allosteric site heretofore never 
observed in FBPase structures.  Inhibition by Glc-6-P was shown to be synergistic with AMP 
inhibition and capable of reversing the activation of the enzyme by PEP.  Furthermore, 
residues which bind Glc-6-P are conserved in organisms which possess the anion activation 
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site for PEP.  The implications of this regulation in bacteria and the potential for 
antimicrobial development are also discussed therein.   
Chapter V describes new structures of both the mammalian enzyme and the bacterial 
enzyme with the inhibitor fructose-2,6-bisphosphate (Fru-2,6-P2) bound.  The investigation 
shows, for the first time, that Fru-2,6-P2 induces a conformational change in porcine FBPase 
similar to the change induced by AMP and that a similar change does not occur in the 
bacterial enzyme.  These observations can explain the synergy between AMP and Fru-2,6-P2 
inhibition observed in the mammalian and yeast enzymes, but not in the bacterial enzyme.  A 
plausible structural mechanism for the induction of the quaternary change by Fru-2,6-P2 in 
mammalian FBPase is described, along with differences in the E. coli enzyme which may  
account for the lack of synergism in the bacterial enzyme.  Implications in the treatment of 
Type II diabetes are also addressed.  Finally, general conclusions to the work appearing in 
the previous chapters and potential future directions for work with mammalian and bacterial 
fructose-1,6-bisphosphatases are described in Chapter VI.   
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Abstract 
Fructose-1,6-bisphosphatase (FBPase) governs a key step in gluconeogenesis, the 
conversion of fructose 1,6-bisphosphate into fructose 6-phosphate.  In mammals, the enzyme 
is subject to metabolic regulation, but regulatory mechanisms of bacterial FBPases are not 
well understood.  Presented here is the crystal structure (resolution, 1.45 Å) of recombinant 
FBPase from Escherichia coli, the first structure of a prokaryotic Type I FBPase.  The E. coli 
enzyme is a homotetramer, but in a quaternary state between the canonical R- and T-states of 
porcine FBPase.  Phe15 and residues at the C-terminal side of the first α-helix (helix H1) 
occupy the AMP binding pocket.  Residues at the N-terminal side of helix H1 hydrogen bond 
with sulfate ions buried at a subunit interface, which in porcine FBPase undergoes significant 
conformational change in response to allosteric effectors.  Phosphoenolpyruvate and sulfate 
activate E. coli FBPase by at least 300%.  Key residues that bind sulfate anions are conserved 
amongst many heterotrophic bacteria, but are absent in FBPases of organisms that employ 
fructose 2,6-bisphosphate as a regulator.  These observations suggest a new mechanism of 
regulation in the FBPase enzyme family: anionic ligands, most likely phosphoenolpyruvate, 
bind to allosteric activator sites, which in turn stabilize a tetramer and a polypeptide fold that 
obstructs AMP binding.  
 
Introduction 
Fructose-1,6-bisphosphatase (D-fructose-1,6-bisphosphate 1-phosphohydrolase, EC 
3.1.3.11; FBPase1) is a key enzyme of the gluconeogenic pathway, hydrolyzing fructose 1,6-
bisphosphate (Fru-1,6-P2) to fructose 6-phosphate (Fru-6-P) and inorganic phosphate (Pi) (1, 
2).  In Escherichia coli, the most likely role of FBPase is the generation of five-carbon 
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precursors for nucleotide and polysaccharide production (3, 4).  Microbial strains without 
FBPase (gene deletion mutants) cannot grow on gluconeogenic substrates, but thrive on 
glucose or other hexoses (3). 
FBPase and fructose-6-phosphate-1-kinase are constitutive enzymes in E. coli, and in 
the absence of some kind of coordinate regulation, define a futile cycle (5).  Futile cycling, 
however, is minimal under glycolytic (6) and gluconeogenic (7) conditions, and hence 
FBPase must be under metabolic control.  In mammals, AMP and fructose 2,6-bisphosphate 
(Fru-2,6-P2) synergistically inhibit FBPase (8).  Fru-2,6-P2, the concentration of which is 
subject to hormonal control, directly inhibits FBPase by binding to its active site, whereas 
AMP binds to an allosteric effector site (5, 9, 10) and induces a conformational change, 
converting the enzyme from an active quaternary conformation (R-state) to an inactive form 
(T-state) (11-13).  In contrast, little is known regarding the regulation of FBPase in E. coli.  
AMP is a potent inhibitor of the E. coli enzyme (4, 14-16), but Fru-2,6-P2 is not present.  
(Fru-2,6-P2, however, does inhibit E. coli FBPase in assays (15, 16)).  Dynamic regulation by 
AMP alone is unlikely, because AMP concentrations in vivo remain relatively constant under 
gluconeogenic and glycolytic conditions (17). 
Donahue was the first to classify prokaryotic FBPases by sequence homology (18).  
Investigators now suggest five FBPase types (19).  Types I-III are primarily in Bacteria, Type 
IV in Archaea and Type V in thermophilic prokaryotes from both domains.  Eukaryotic 
FBPases are homologous to prokaryotic Type I enzymes.  Crystal structures are available for 
Types IV and V FBPases and for mammalian and chloroplast FBPases, but no structure of an 
FBPase from Bacteria is available. 
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FBPase is a target for potential drugs in the treatment of Type II diabetes (20-22).  
Novel inhibitors have been developed (20, 21), and in one case, knowledge of structure and 
mechanism contributed to the rational design of a new inhibitor (22).  An important property 
of mammalian FBPase, synergism in Fru-2,6-P2/AMP inhibition, however, is not understood 
in terms of a specific molecular mechanism.  Moreover, no example is known of a mutant or 
wild-type mammalian FBPase that lacks synergism without significant disruption of AMP or 
Fru-2,6-P2 inhibition.  Fru-2,6-P2 and AMP individually are potent inhibitors of E. coli 
FBPase, but exhibit no synergism (15).  The sequence identity (41%) of the E. coli and 
porcine enzymes suggest similar folds.  Other studies indicate the existence of an allosteric 
AMP binding site and a tetrameric subunit organization for the E. coli enzyme (14, 16).  
Hence, differences in the conformational responses of E. coli and porcine FBPases to AMP 
and/or Fru-2,6-P2 could reveal the molecular basis of AMP/Fru-2,6-P2 synergism. 
Reported here is the high-resolution structure of Type-I FBPase from E. coli.  The 
structure reveals a homotetramer between the canonical R- and T-states of porcine FBPase 
(11).  Sulfate anions appear at the interface between top and bottom subunit pairs of the 
tetramer.  Sulfate and phosphoenolpyruvate (PEP) enhance activity of the E. coli enzyme by 
at least 300%.  Anionic ligands likely mimic a physiological effector that stabilizes E. coli 
FBPase as an active tetramer, a hypothesis consistent with previous reports of dilution-linked 
inactivation (4, 14).  The true physiological activator is probably PEP, an inhibitor of E. coli 
fructose-6-phosphate-1-kinase (23), and an activator of FBPases in other prokaryotic 
organisms (18, 24-26).  Sequence alignments reveal a number of organisms with Type I 
FBPases that probably possess the anion binding site of the E. coli enzyme.  The anion 
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binding site, however, is not present in organisms that employ Fru-2,6-P2 in the regulation 
FBPase activity. 
 
Experimental: Materials and Methods 
Materials— Fru-1,6-P2, NADP+, PEP, leupeptin, ampicillin, phenylmethylsulfonyl 
fluoride (PMSF), DEAE-Sepharose and Phenyl-Sepharose came from Sigma and kanamycin 
sulfate from Invitrogen.  VENT DNA-polymerase and all restriction enzymes were 
purchased from New England BioLabs.  Glucose 6-phosphate dehydrogenase and 
phosphoglucose isomerase were from Roche Applied Sciences.  The Iowa State University 
DNA Sequencing and Synthesis Facility produced deoxyoligonucleotides.  All other 
chemicals were of reagent grade or equivalent. 
Cloning E. coli FBPase― The fbp gene that encodes Type I FBPase in E. coli (27) 
was cloned from genomic DNA isolated from strain XL1-Blue (Stratgene) by primer 
extension using polymerase chain reactions (PCR).  Forward (5´-GTATCGACCATATG-
AAAACGTTAGGTGAATTTATTG-3´) and reverse (5´-CAGAATTCTTACGCGTCCG-
GGAACTCACGG-3´) primers introduced NdeI and EcoRI sites, respectively (sites 
underlined).  The initial round of PCR employed VENT DNA polymerase.  The amplified 
product was the template for a second PCR, using the same primers and the BIO-X-ACT 
Short DNA Polymerase (Midwest Scientific), which leaves a 3´-A overhang.  The resulting 
oligonucleotide was ligated into the pGEM-T Easy Vector (Promega) and the resulting 
plasmid used to transform electrocompetent XL1-Blue cells.  Transformants were selected by 
growth on LB-agarose supplemented with 50 µg/mL ampicillin while recombinants were 
selected by blue/white screening.  Plasmid DNA was isolated from cultures grown from 
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single colonies.  The presence of the insert was verified by digestion with EcoRI and gel 
electrophoresis. 
The internal NdeI site within the fbp gene was eliminated by PCR using the 
mutagenic primer 5´-CTTTGTCGGCAACGACCACATGGTTGAAATGTCGAACGC-3´ 
and its reverse compliment to introduce a silent mutation (base change underlined).  Parental 
methylated DNA was digested with DpnI, and DH5α cells were transformed with the 
resulting nicked plasmid.  Plasmids from single colonies were isolated, digested with NdeI, 
and separated by gel electrophoresis, using non-mutated plasmid as a control.  The desired 
mutation was confirmed by DNA-sequencing by the Iowa State University DNA Sequencing 
and Synthesis Facility.  The resulting construct was amplified by PCR, and then digested 
with NdeI and EcoRI.  Simultaneously the bacterial protein expression vector pET-24b 
(Novagen), carrying the kanr selectable marker, was digested with NdeI and EcoRI and the 
cut plasmid isolated by gel electrophoresis.  The excised oligonucleotide and vector DNA 
were purified, ligated, and transformed as previously described, using the cut and uncut 
vectors as negative and positive controls, respectively.  The final plasmid (pECFBP) was 
verified by DNA-sequencing. 
Expression and Purification of Native and Selenomethionine-Substituted E. coli 
FBPase― Separate preparations of native and selenomethionine-substituted enzyme were 
used for the kinetic and structural investigations, respectively.  FBPase-deficient E. coli 
strain DF657 [tonA22, ompF627(T2R), relA1, pit10, spoT1, ∆(fbp)287; Genetic Stock Center 
at Yale University, New Haven, CT] was transformed by the pECFBP plasmid and plated 
onto LB-agarose supplemented with 30 µg/mL kanamycin sulfate.  A single-colony inoculant 
(100 mL LB-kanamycin) grew (with shaking, 37 oC) for 12 hrs.  Two percent inoculum was 
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added to 4 L LB-kanamycin.  The culture grew (with shaking, 37 ºC), to an O.D.600 of 1.0, at 
which time transcription was induced by the addition of isopropyl-β-D-thiogalactopyranoside 
(IPTG, final concentration, 0.85 mM).  The culture was maintained (with shaking, 37 ºC) for 
an additional 12 hrs.  Selenomethionine-substituted protein was produced as described 
previously with all growth steps at 37 oC (28). 
Modifications to the protocol of Kelley-Loughnane, et al. (16) led to purified protein 
in a single day.  All buffers employed after cell lysis were degassed (stirring under vacuum) 
and contained 0.2 mM ethylenediaminetetraacetic acid (EDTA) and 5 mM dithiothreitol 
(DTT).  Cells were collected by centrifugation (3,000xg) and re-suspended in 75 mL of lysis 
buffer (40 mM KH2PO4/K2HPO4, pH 7.0, 0.1 mM phenylmethylsulfonyl fluoride (PMSF), 1 
mM EDTA, 5 µg/mL leupeptin, and 1 mM β-mercaptoethanol) for disruption by French 
press.  Insoluble debris was removed by centrifugation (30 min., 33,000xg) prior to 
ammonium sulfate fractionation.  Precipitated protein was collected by centrifugation from 
40–70% levels of saturated (NH4)2SO4, and re-dissolved in 40 mM NaH2PO4, pH 7.2, and 
(NH4)2SO4 (40% of saturation).  Protein was loaded onto a Phenyl-Sepharose column, 
washed with the same buffer, and eluted by a step gradient in (NH4)2SO4 (20% followed by 
14% of saturation).  Combined fractions of highest specific activity were reduced in volume 
to 30 mL using an Amicon concentrator (YM 30,000 membrane).  Protein was passed 
through a desalting column (Sephadex G-50 equilibrated with 40 mM NaH2PO4, pH 7.2), 
loaded onto a DEAE-Sepharose column, (equilibrated with 0.1 M NaCl, 40 mM NaH2PO4, 
pH 7.2) and then eluted with a linear gradient in NaCl (0.1–0.5 M).  Pooled fractions of 
highest specific activity were desalted (Sephadex G-50 column, equilibrated with 5 mM Tris-
malonate, pH 7.4).  Enzyme (0.75 mg/mL) used for kinetic studies was frozen in this buffer, 
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whereas enzyme used for crystallization experiments was concentrated to 15 mg/mL and 
filtered through a 0.22 µM filter.  Protein was flash frozen in 200 µL aliquots using a dry-ice 
ethanol bath and stored at –80 oC.  Protein concentrations were determined by the method of 
Bradford (29), using bovine serum albumin as a standard.  Protein purity was monitored by 
sodium dodecylsulfate-polyacryamide gel electrophoresis (30).  N-terminal sequencing and 
mass determinations of purified proteins were performed at the Iowa State University Protein 
Facility, using an Applied Biosystems Voyager System 6075 Matrix Assisted Laser 
Desorption/Ionization-Time-of-Flight Mass Spectrometer (MALDI-TOF MS). 
Crystallization of E. coli FBPase— Crystals were grown by hanging drop in vapor 
diffusion VDX-plates (Hampton Research).  Droplets contained 2 µL of a protein solution 
(15 mg/mL of the selenomethionine-substituted FBPase, 20 mM DTT, 0.2 mM EDTA, and 5 
mM each of Fru-1,6-P2, Fru-2,6-P2 and MgCl2) and 2 µL of a precipitant solution (2.0 M 
(NH4)2SO4) and were equilibrated over 500 µL of precipitant solution.  Equal-dimensional 
crystals (0.2-0.4 mm) grew within 3 days at 22 oC.  Crystals were immersed for 20 seconds in 
the precipitant solution, supplemented with DTT, ligands and 27% (v/v) glycerol, before 
freezing directly in a cold stream of nitrogen. 
Data Collection— Crystals were screened for diffraction at Iowa State University on 
a Rigaku R-AXIS IV++ rotating anode/image plate system using CuKα radiation from an 
Osmic confocal optics system at a temperature of 110 K.  High resolution data were collected 
at 100 K on Beamline 4.2.2 of the Advanced Light Source, Lawrence Berkeley Laboratory.  
The program d*trek (31) was used to index, integrate, scale and merge intensities, which 
were then converted to structure factors using the CCP4 (32) program TRUNCATE (33). 
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Structure Determination and Refinement— A molecular replacement solution was 
obtained using the program AMORE (34) and the model for R-state porcine FBPase (PDB 
accession identifier 1CNQ), from which residues 52–72 and all ligand and water molecules 
had been removed.  Residues for the E. coli enzyme were manually fit to omit density, using 
the program XTALVIEW (35).  The resulting model using CNS (36) underwent simulated 
annealing from 3000 to 300 K in steps of 25 K, followed by 100 cycles of energy 
minimization and thermal parameter refinement.  Force constants and parameters of 
stereochemistry were from Engh and Huber (37).  Restraints for thermal parameter 
refinement were as follows: 1.5 Å2 for bonded main-chain atoms, 2.0 Å2 for angle main-chain 
atoms and angle side-chain atoms, and 2.5 Å2 for angle side-chain atoms.  Ligands and water 
molecules were fit to omit electron density until no improvement in Rfree was evident.  Water 
molecules with thermal parameters above 50 Å2 or more than 3.2 Å from the nearest 
hydrogen bonding partner were removed from the final model. 
Comparison of Porcine and E. coli FBPases— Construction of dimer and tetramer 
models from the original monomer model, as well as pair-wise least-squares superpositions 
of E. coli FBPase and porcine liver FBPase were accomplished using the CCP4 programs 
PDBSET (38) and LSQKAB (39).  The canonical R- and T-states of porcine FBPase used in 
superpositions have PDB identifiers 1CNQ and 1EYK, respectively, whereas IT- and IR-states 
have identifiers 1Q9D and 1YYZ, respectively.  The angle of rotation of subunit pairs in 
various quaternary states of FBPases is sensitive to the subset of residues used in the least-
squares fit (40).  By convention, Cα atoms of porcine FBPase residues 33–49, 75–265, 272–
330 are used; however, gross structure differences and residue insertions dictate the use of a 
slightly modified subset in comparisons between porcine and E. coli FBPase.  Cα atoms used 
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in all least-squares superpositions are porcine FBPase residues 33–49, 75–106, 112–140, 
148–232, 239–265, and 272–330, and the structurally corresponding E. coli FBPase residues 
25–41, 67–98, 104–132, 142–226, 234–260, and 267–325.  This modified residue set does 
not significantly alter the angle of rotation represented in the R- to T-state transition of 
porcine FBPase. 
Kinetic Experiments—Assays for FBPase activity employed the coupling enzymes 
phosphoglucose isomerase and glucose-6-phosphate dehydrogenase and monitored formation 
of NADPH by either absorbance at 340 nm or fluorescence emission at 470 nm (40).  Assays 
(total volume, 2 mL) were performed at 22 oC in 50 mM Hepes, pH 7.5, with 0.1 mM EDTA 
and 150 µM NADP+.  Saturating levels of Fru-1,6-P2 (40 µM) and MgCl2 (10 mM) were used 
in assays to measure specific activity and ligand activation.  Reactions were initiated by the 
addition of 1.4 µg enzyme (specific activity determinations) or by incubating (1 hr.) the 
enzyme in assay mixtures without MgCl2, and subsequently initiating the reaction by the 
addition of metal.  For activation assays, the coupling enzymes were dialyzed against a 1000-
fold volume of 50 mM Hepes, pH 7.5, to remove ammonium sulfate that would otherwise be 
present at ~3 mM in all assays. 
Sequence Alignments—Multiple sequence alignments employed the program 
CLUSTALW (41).  Pair-wise alignments, which served as the basis for calculating sequence 
identity, employed the program ALIGN (42). 
 
Results 
Enzyme Purity—Native and selenomethionine-substituted preparations of E. coli 
FBPase represented more than 30% of the soluble protein in the cell lysate.  Preparations of 
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E. coli FBPase, isolated by following a multi-day protocol, were proteolyzed near the N-
terminus (confirmed by Edman degradation) and had relatively low specific activities.  
Kinetic parameters for porcine FBPase are sensitive to truncations near the N-terminus (43), 
and in order to avoid any modification of the N-terminal residues of E. coli FBPase, we 
developed a streamlined protocol that provided enzyme free of proteolysis (confirmed by N-
terminal sequencing and by electron density in the crystal structure).  The first residue in E. 
coli FBPase is an unblocked methionine (first residue of the translated DNA sequence).  
Retention of the N-terminal methionine is consistent with lysine at position two of the 
sequence; long side-chains at sequence position two generally prevent E. coli methionyl-
aminopeptidase from excising the N-terminal methionine (44).  Final enzyme preparations 
are at least 95% pure as evidenced by sodium dodecylsulfate-polyacrylamide gel 
electrophoresis and have specific activities of 40 U/mg. 
E. coli FBPase has six methionine residues per monomer.  Mass analyses of native 
and selenomethionine-substituted proteins indicate a mass increase of 261±30 Da, 
corresponding to more than a 90% replacement of methionine with selenomethionine.  Non-
denaturing gel electrophoresis revealed a ladder of protein bands indicative of high molecular 
weight aggregates.  Others have observed aggregation of E. coli FBPase (14, 16), a condition 
we sought to avoid in crystallizing the enzyme.  The inclusion of 20 mM DTT in protein 
solutions prevented ladder formation and improved crystal growth. 
Kinetic Parameters—Native and selenomethionine-substituted enzymes were 
kinetically indistinguishable: kcat, Km for Fru-1,6-P2 and Ka for Mg2+ are 24 s–1, 1.7±0.1 µM 
and 1.0±0.1 mM, respectively.  The Hill coefficients for both Fru-1,6-P2 and Mg2+ are 
1.1±0.1.  These values are similar to those reported previously for E. coli FBPase (4, 14, 16), 
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and differ from the porcine enzyme principally in the Hill coefficient for Mg2+, which for 
porcine FBPase is 1.9±0.1 (45). 
Structure of E. coli FBPase (PDB identifier 2GQ1)— Type I FBPase from E. coli has 
the same overall sugar-phosphatase fold and tetrameric subunit organization as other Type I 
FBPases for which structural information is available (Fig. 1a) (11, 46, 47).  Crystals belong 
to the space group I222 (a=45.6, b=81.3, c=170.1 Å) with one subunit of the tetramer in the 
asymmetric unit.  Data also were collected on native protein crystals in-house to a resolution 
of 2.5 Å.  The native and selenomethionine-substituted structures exhibited no differences 
beyond coordinate uncertainty.  Hence, we report here only the results of the high-resolution, 
selenomethionine-substituted structure (Table 1). 
Each subunit has 7.5 bound sulfate ions.  The “half-sulfate” (Sulfate341) is on the 
crystallographic twofold axis that relates subunits C1 and C2 (and subunits C3 and C4) (Fig. 
1).  Sulfate343 is at a lattice contact between adjacent tetramers, and Sulfate346 at a locus that 
maps onto the AMP binding site of porcine FBPase (48).  Sulfate348 and Sulfate345 are at the 
1-phosphoryl- and 6-phosphoryl-binding sites of Fru-1,6-P2, respectively, as defined by 
structures of porcine FBPase (11, 49).  An additional sulfate ion (Sulfate342) binds at a locus 
occupied by the side-chain of Asp68 of the porcine R-state structure (49).  Sulfate344 binds at 
the C1–C4 interface, roughly at the location of the carboxyl group of Glu192 in porcine 
FBPase (The corresponding residue is Val186 in the E. coli enzyme), and 8.5 Å away from a 
symmetry-related partner (Fig. 2).  Sulfate347 binds on the surface of the subunit at a position 
of no known significance.  No other ligands are present, even though fructosyl-phosphates 
were present in the crystallization experiments. 
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Fig. 1.  Overview of E. coli FBPase.  The tetramer is shown with subunits labeled as for mammalian 
FBPases.  Locations of the presumed active site and AMP binding site are indicated in subunit C2, as 
are the bound sulfate molecules.  Helices H1 and H2 participate in interactions across the C1–C4 
interface as described in the text.  Parts of this drawing were prepared with MOLSCRIPT (55). 
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Fig. 2.  Stereoview of the anion activation site.  Electron density is from an omit map (contour level 
1σ, cutoff radius 1.5 Å) covering Sulfate344 and residues in its vicinity.  The arrow in Fig. 1 indicates 
the viewing direction is for this figure.  Parts of this drawing were prepared with XTALVIEW (35). 
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Table 1.  Statistics of data collection and refinement for E. coli FBPase.  Space group and 
unit cell parameters are in the Results section. 
 
Resolution (Å) 44.04–1.45 (1.50–1.45)a 
Number of reflections 392,636 
Unique reflections/reflections used in 
refinement 56,471 
Average redundancy 6.95 (6.59)a 
% Completeness 99.9 (99.9)a 
Rmergeb 0.069 (0.293)a 
I/σ(I) 13.3 (5.2)a 
Number of atoms 2807 
Number of solvent sites 324 
Rfactorc 21.9 
Rfreed 23.2 
Mean B for Protein (Å2) 18 
Mean B for SO42– (Å2) 46 
Root mean squared deviations:  
   Bond lengths (Å) 0.004 
   Bond angles 1.2 
   Dihedral angles 22.2 
   Improper angles 0.70 
 
Table I.  Footnotes. 
 
aValues in parentheses are for the last shell of data collection. 
bRmerge = ΣjΣi | Iij  – <Ij> | /ΣiΣjIij, where i runs over multiple observations of the same intensity and j 
runs over all the crystallographically unique intensities. 
cRfactor = Σ || Fobs | – | Fcalc || /Σ | Fobs |, where | Fobs | > 0 
dRfree based upon 10% of the data randomly culled and not used in the refinement 
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Residues of the deposited model are in good electron density; however, residues 42–
63, which correspond to the dynamic loop of the porcine enzyme, are without electron 
density and have been omitted.  The dynamic loop in porcine FBPase takes on either an 
engaged or disordered conformation in the absence of AMP (48, 49).  The disordered loop in 
the E. coli structure probably may be a consequence of the high concentration of sulfate. 
E. coli FBPase is in an intermediate quaternary state relative to the canonical R- and 
T-states of porcine FBPase, being 6o from the R-state and 8o from the T-state.  (Quaternary 
states of porcine FBPase are defined by rotations of the C1–C2 subunit pair with respect to 
the C3–C4 subunit pair about the vertical molecular twofold axis in Fig. 1).  The quaternary 
state of E. coli FBPase is most similar to the IR-state of the porcine enzyme (40); however, no 
conclusion is possible regarding ligand-induced changes in the quaternary state of the E. coli 
enzyme. 
The segment (residues 12–18) connecting the first and second α-helices (helices H1 
and H2, respectively) of E. coli FBPase differs significantly from the corresponding element 
of the porcine enzyme.  The connecting loop in porcine FBPase bears residues (such as 
Thr27) critical to the recognition of AMP, and in fact, Thr27, Gly28, Glu29, Thr31, Lys112, 
Tyr113, and Arg140 of porcine FBPase have close analogs in E. coli FBPase.  Notwithstanding 
sequence conservation, the AMP pocket in E. coli FBPase is not open to AMP ligation.  
Although Sulfate346 maps near the 5´-phosphoryl group of AMP in porcine FBPase, Phe15 of 
the helix H1–H2 connecting loop occupies what would be the binding pocket for AMP (Fig. 
3).  Moreover, residue-types flanking Phe15 differ significantly in the E. coli and porcine 
enzymes.  Hence, the local fold of the polypeptide chain sterically blocks AMP.  AMP 
ligation, as observed in mammalian FBPase, would necessitate a large conformational  
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Fig. 3.  AMP binding sites of porcine and E. coli FBPases.  AMP bound to the allosteric inhibitor 
site of porcine FBPase is shown (left) with the corresponding view of the presumed AMP binding site 
of E. coli FBPase (occupied by Phe15) (right).  Dotted lines are selected donor-acceptor interactions of 
3.2 Å or less.  The icon indicates viewing direction (arrow) and region of the tetramer being viewed 
(shaded black).  This drawing was prepared with MOLSCRIPT (55). 
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change in the E. coli enzyme that would likely perturb helices H1 and H2.  We speculate in 
the discussion, that such a conformational change is part of a mechanism of allosteric 
regulation of catalysis. 
Many residues are conserved between porcine and E. coli FBPases, but a number of 
critical residues are missing from the C1–C4 interface, most notably residues corresponding 
to Asn35, Thr39, and Glu192 of the porcine enzyme (Fig. 4).  Glu192 in porcine FBPase forms 
critical hydrogen bonds between subunits C1 and C4 in the R- and T-states, interacting with 
Thr39 and Lys42.  Glu192 is valine in E. coli FBPase, and Thr39 a leucine.  Sulfate344 binds in 
place of the carboxyl group of Glu192, filling a positively charged cavity between subunits C1 
and C4.  Eight residues define this anion-binding site, six of which differ in type from 
corresponding residues in porcine FBPase.  Porcine residues Thr14, Asn35, Cys38, Thr39, Ser88, 
and Glu192 are Gly5, Ser27, Lys30, Leu31, Arg80, and Val186 in E. coli FBPase.  Only Lys42 and 
Thr12 in the porcine enzyme are conserved as Lys34 and Thr3 in E. coli FBPase.  Five 
residues, Thr3, Gly5, Lys30, Lys34, and Arg80, contribute interactions to Sulfate344 (Fig. 4).  In 
the R-state porcine enzyme, Asn35 hydrogen bonds across the C1–C4 interface through water 
molecules and interacts directly with Thr14 of the same subunit.  These interactions are 
missing in E. coli FBPase; the corresponding residues (Ser27 and Gly5, respectively) are 
considerably smaller and allow Sulfate344 to interact with backbone amide 5 of the first turn 
of helix H1.  The presence of several water molecules in the cavity suggests a binding site for 
a larger ligand. 
Activation of E. coli FBPase— The specific activity of E. coli FBPase decreases with 
dilution in the standard assay mixture, whereas that of porcine FBPase is constant (data not 
shown).  The decline in specific activity of the E. coli enzyme in response to dilution occurs 
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Fig. 4.  C1–C4 interface of porcine and E. coli FBPases.  Dotted lines represent donor-acceptor 
interactions of 3.2 Å or less.  Asn35, Thr39 and Glu192 hydrogen bond across the interface of porcine 
FBPase (left), but are not present in E. coli FBPase (right).  Instead the corresponding region of E. 
coli FBPase has a pair of symmetry related sulfate ions (Sulfate344), which overlay the carboxyl 
groups of Glu192 in porcine FBPase and interact extensively with positively charged residues across 
the C1–C4 interface.  The icon indicates viewing direction (arrow) and region of the tetramer being 
viewed (shaded black).  This drawing was prepared with MOLSCRIPT (55). 
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in minutes and is not temperature dependent, but is affected by certain salts.  PEP and 
ammonium sulfate activate E. coli FBPase in assays initiated by the addition of Mg2+ 
(enzyme is at equilibrium prior to the initiation of assays).  The activity of E. coli FBPase 
increases more than 300% in the presence of 20 mM (NH4)2SO4 (Fig. 5).  Activation is due 
to the sulfate anion; NH4Cl only causes inhibition of the E. coli enzyme (Fig. 5), and other 
forms of sulfate (Na2SO4) and KH2PO4 exhibit similar activation effects (data not shown).  
Under identical conditions, porcine FBPase is also activated to a lesser extent by (NH4)2SO4, 
but the observed activation is due to NH4+ (50, 51), and can be reproduced by the addition of 
NH4Cl.  Ammonium sulfate concentrations above 20 mM progressively inhibit the E. coli 
enzyme, presumably due to the binding of sulfate anions to the active site.  PEP is a far more 
potent activator of E. coli FBPase, causing approximately 300% activation at a concentration 
of 2 mM (Fig. 5).  Fifty percent of maximum activation occurs at a concentration of ~40 µM 
PEP. 
Sequence Alignments of Type I FBPases—Sequence alignments of more than 100 
Type I bacterial and eukaryotic FBPases appears in an abbreviated format in Table 2.  
FBPases fall into three groups: (i) sequences that have the signature residues of the anion 
binding site and blocked AMP site (residues corresponding in type and position to Gly5, 
Phe15, Lys30, and Arg80 of E. coli FBPase), (ii) sequences that have a glutamate 
corresponding to Glu192 of porcine FBPase, and (iii) sequences that have neither signature 
residues of an anion binding site nor a residue corresponding to Glu192 of the porcine 
enzyme.  Notably, no sequence falls into a fourth category, matching both Glu192 of porcine 
FBPase and signature residues of the  
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Fig. 5.  Response of E. coli FBPase to sulfate and PEP.  Recombinant E. coli FBPase was 
combined with the standard assay mixture (see methods section) supplemented with either (NH4)2SO4 
or NH4Cl (top) or with PEP (bottom).  Assay mixtures were incubated 1 hr at 22 oC prior to the 
addition of MgCl2.  NH4Cl (●) inhibits E. coli FBPase.  (NH4)2SO4 (■) activates E. coli FBPase, with 
an apparent maximal activation of 300% of at 20 mM (NH4)2SO4.  PEP (♦) activates E. coli FBPase, 
with an apparent maximal activation of 300%.  Error bars represent ±1σ deviation.   
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Table 2.  Conservation of the anion activation and AMP sites.  Type-I FBPase sequences from more 
than 100 species of eukaryotes and bacteria were aligned using the program CLUSTALW (41). Listed 
below are results for a representative set of sequences for five residues, referenced by number to the 
porcine and E. coli FBPase sequences.  Residues similar in type to the signature residues of E. coli FBPase 
and Glu192 of porcine FBPase are shaded.  Names of species that have FBPases with at least three of four 
signature residues are shaded.  The overall sequence identity to E. coli FBPase was calculated by ALIGN 
(42). 
 
Residue number in porcine/E. coli 
FBPase Species 
Percent 
identity 
to E. coli 
FBPase 14/5 –/15 38/30 88/80 192/186 
Homo Sapian (liver) 42 T – C S E 
Homo Sapian (muscle) 40 T – L S E 
Sus Scrofa (liver) 41 T – C S E 
Rattus norvegicus (liver) 40 T – C S E 
Xenopus tropicalis 44 T – C S E 
Brachydanio rerio 43 T – C S E 
Drosophila melanogaster 46 T F Q S E 
Schistosoma japonicum 44 T F Q S E 
Caenorhabditis elegans 45 Q H L S E 
Solanum tuberosum (cytoplasmic) 45 T H V S E 
Arabidopsis thaliana (cytoplasmic) 44 T Y V S E 
Oryza sativa (chloroplast) 37 T G S S E 
Pisum sativum (chloroplast) 38 T G V S E 
Saccharomyces cerevisiae 40 P F Q S E 
Yarrowia lipolytica 41 T V Q S E 
Leishmania_major 40 T H Q S E 
Trypanosoma brucei 40 M M Q S E 
Toxoplasma gondii 52 G L K R T 
Mannheimia succiniciproducens 70 D Y R R T 
Pasteurella multocida 70 G Y R R V 
Haemophilus influenzae 70 S Y R R T 
Haemophilus_ducreyi 66 G Y R R T 
Salmonella_typhi 97 G F K R V 
Escherichia coli 100 G F K R V 
Photorhabdus luminescens 84 G F K R V 
Erwinia carotova 87 G F K R V 
Yersinia pseudotuberculosis 83 G F K R V 
Vibrio cholerae 76 G F R R T 
Photobacterium profundum 73 G F K R V 
Chlorobium tepidum 52 E Y A H E 
Bordetella parapertussis 47 T A A G S 
Leptospira interrogans 45 S L V S E 
Nostoc punctiforme 40 S F A S E 
Alcaligenes eutrophus 40 T Y A G E 
Shewanella oneidensis 43 A – A D E 
Geobacter sulfurreducens 37 R – A S E 
Xanthobacter flavus 34 H V A – L 
Campylobacter coli 31 – – Q C N 
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anion binding site.  Hence, glutamate at position 192 and the anion binding site may be 
mutually exclusive.  Approximately 65% of bacterial sequences lack glutamate at positions 
corresponding to 192 of porcine FBPase, and of these approximately one-half have the 
signature residues of an anion-binding site.  Only one eukaryotic organism, the pathogenic 
protozoa Toxoplasma gondii, has residues corresponding in position and type to the anion-
binding site.  Curiously, all species known to produce Fru-2,6-P2 always have FBPases with 
glutamate at positions corresponding to 192 of porcine FBPase.  No evidence supports the 
existence of Fru-2,6-P2 in T. gondii. 
With the exception of T. gondii, organisms that have FBPases with signature residues 
of the anion-binding site are heterotrophic Bacteria, and like E. coli, are members of the 
phylum Proteobacteria and class Gammaproteobacteria.  Most are pathogens, a bias due 
perhaps to the disproportionate number of FBPase sequences available for pathogenic 
organisms.  The anion-binding site may be present in all known Type I FBPases from the 
orders Enterobacteriales, Vibrionales, and Pasteurellales, all of which include important 
pathogens. 
Discussion 
The structure here indicates a subunit arrangement for the E. coli enzyme, similar to 
that of mammalian FBPase tetramers.  Enzyme concentrations in crystallization experiments, 
however, are approximately 20,000-fold higher than those of assays.  The E. coli enzyme 
remains a tetramer at levels 20-fold less than those of crystallization experiments (14, 16), 
but its apparent mass decreases slightly with concentration (14), suggesting the possibility of 
a dissociated state of the enzyme. 
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Porcine FBPase undergoes spontaneous subunit exchange (45, 52, 53).  In the 
presence of Fru-1,6-P2 or Fru-2,6-P2, exchange reactions involve only dimers of the tetramer 
(45, 53).  As the active site is shared between subunits C1 and C2, dimer exchange probably 
entails separation at the C1–C4 interface.  Protein-protein hydrogen bonds between subunits 
C1 and C4 are few in number in the E. coli enzyme, suggesting that in the absence of an 
anion at the C1–C4 interface the E. coli tetramer may be unstable relative to the mammalian 
tetramer.  At low protein concentrations, and in the absence of specific anionic ligands, the 
bacterial enzyme may dissociate into less active (or inactive) dimers.  Sulfate ions form 
extensive connections between subunits C1 and C4, and presumably activate the enzyme by 
stabilizing a tetramer. 
If indeed E. coli FBPase requires an anion to assemble into a fully active tetramer, 
then enzyme activity should be sensitive to concentrations of anions and protein.  Large 
losses in activity have been observed after dialysis steps that remove ammonium sulfate (4), 
or by dilution of the enzyme (4, 14).  Most striking is the sensitivity of E. coli FBPase to the 
method of assay.  The enzyme loses as much as 70% of its activity upon a 1000-fold 
dilution/incubation in the standard assay (4, 14), a behavior not exhibited by porcine FBPase.  
This loss of activity is even more severe (in excess of 80%) after dialysis of the (NH4)2SO4 
from coupling enzymes used in assays. 
PEP relieves AMP inhibition of E. coli FBPase (14, 15) and activates FBPases from 
E. coli (Fig. 5) and other prokaryotic organisms (18, 24-26).  PEP levels in E. coli change 
more than 10-fold between glycolytic and gluconeogenic growth (54), hence the suggestion 
by Babul et al. (14) that PEP is a physiological regulator of E. coli FBPase.  If PEP is a 
physiological regulator of FBPase, then it must bind to the enzyme, but where?  Observations 
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of similar phenomena in Type III FBPases have led others to suggest competition between 
PEP and AMP for the same site (25), but such a mechanism is unlikely for E. coli FBPase: 
AMP-binding residues of porcine FBPase are present in E. coli FBPase and yet PEP has no 
effect on AMP inhibition of mammalian systems (2).  The binding of PEP to the active site 
can only cause inhibition.  So the anion-binding site at the C1–C4 interface remains as the 
most probable site for PEP association.  A PEP-bound structure of E. coli FBPase will 
require new crystallization conditions that avoid high salt concentrations, but using the 
electron density of the sulfate anion to anchor its phosphoryl group, one can easily model the 
remaining atoms of PEP into the void of the C1–C4 anion binding pocket (Fig. 6). 
A binding site for PEP, distinct from AMP, however, creates a new challenge: What 
mechanism causes the apparent mutual exclusivity in the binding of PEP and AMP?  Unlike 
the R-state of porcine FBPase, which can bind AMP (40, 53), the sulfate-ligated state of E. 
coli FBPase cannot bind AMP because Phe15 occupies the binding pocket for the nucleotide.  
Important recognition elements for AMP are at the C-terminal side of helix H1, whereas 
important recognition elements for the sulfate anion (the proposed binding site of PEP) are at 
the N-terminal side of helix H1 (Fig. 7).  As AMP binds to E. coli FBPase, the 
conformational perturbation on helix H1 probably disrupts hydrogen bonds to the ligand at 
the C1–C4 interface.  In fact, one of the effects of AMP-ligation of porcine FBPase is the 
conformational change in helix H1 that displaces Ile10 (which is at the N-terminal side of 
helix H1) from a hydrophobic pocket (40).  Hence, certain features of the allosteric 
mechanism of AMP inhibition in mammalian FBPases may be evolutionary adaptations of an 
ancient mechanism of allosteric regulation prevalent in Bacteria. 
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Fig. 6.  Model of PEP bound to FBPase at its proposed activation site.  Using the electron density 
of Sulfate344, PEP has been fit into the proposed activation site.  PEP, relative to sulfate, could 
increase direct interactions across the C1–C4.  The icon indicates viewing direction (arrow) and 
region of the tetramer being viewed (shaded black).  This drawing was prepared with MOLSCRIPT 
(55). 
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Fig. 7.  Mutual exclusion in the binding of AMP and anion activators to E. coli FBPase.  Shown 
are orthogonal views of the presumed AMP pocket (occupied by Phe15) and the anion activation site 
occupied by sulfate).  The panel on the right adopts the orientation of Fig. 1, whereas the panel on the 
left is the viewing direction of the arrow in Fig. 1.  If AMP displaces Phe15, the net effect may be the 
movement of helix H1 toward the center of the tetramer as observed in porcine FBPase.  Such a 
movement would displace the anion activator from the C1–C4 interface.  This drawing was prepared 
with MOLSCRIPT (55). 
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Sequence alignments of Type I FBPases from eukaryotic and bacterial sources 
reveals a putative activation site common to heterotrophic bacteria from the class 
Gammaproteobacteria, specifically the orders Entereobacteriales, Vibrionales, and 
Pasteurallales.  These organisms may need to adapt to changing environments and therefore 
may require a mechanism for rapid activation/inactivation of their gluconeogenic pathway.  
As concentrations of AMP are uniform for E. coli growing under glycolytic and 
gluconeogenic conditions (17), FBPase would experience nearly constant inhibition due to 
AMP.  Under glycolytic conditions of growth, concentrations of PEP are low, and AMP 
would effectively inhibit FBPase.  Under gluconeogenic conditions, PEP concentrations are 
high, displacing AMP and activating the enzyme.  Hence, for E. coli and organisms that have 
the putative activation site, FBPase is normally inactive and subject to dynamic allosteric 
activation. 
Glu192 of porcine FBPase is conserved amongst eukaryotic organisms, and is 
prevalent in Bacteria as well.  Approximately 35% of the bacterial FBPases investigated here 
have glutamate at positions corresponding to 192 of porcine FBPase and lack the signature 
residues of an anion activation site.  The side-chain of Glu192 probably accomplishes the task 
of an anion in stabilizing an active tetramer.  Hence, the introduction of Glu192 probably 
resulted in a constitutively active enzyme, thus requiring a new strategy of regulation.  In 
bacterial FBPases that have glutamate at position 192, that mechanism of regulation is 
unclear.  In eukaryotic organisms, a permanently-activated FBPase is subject to dynamic 
inhibition by Fru-2,6-P2.  At some unknown point in evolution dynamic inhibition of FBPase 
by Fru-2,6-P2 became synergistic with AMP. 
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Abstract 
The enteric bacterium Escherichia coli requires fructose-1,6-bisphosphatase (FBPase) 
for growth on gluconeogenic carbon sources.  Constitutive expression of FBPase and 
fructose-6-phosphate-1-kinase, coupled with the absence of futile cycling, implies an 
undetermined mechanism of coordinate regulation involving both enzymes.  Tri-carboxylic 
acids and phosphorylated three-carbon carboxylic acids, all intermediates of glycolysis and 
the TCA cycle, are shown here to activate E. coli FBPase.  The two most potent activators, 
phosphoenolpyruvate and citrate, bind to the sulfate anion site, revealed previously in the 
first crystal structure of the E. coli enzyme.  Tetramers ligated with either phospho-
enolpyruvate or citrate, in contrast to the sulfate-bound structure, are in the canonical R-state 
of porcine FBPase, but nevertheless, retain sterically blocked AMP pockets.  At 
physiologically relevant concentrations, phosphoenolpyruvate and citrate stabilize an active 
tetramer over a less active enzyme form of mass comparable to that of a dimer.  The above 
implies the conservation of the R-state through evolution.  FBPases of heterotrophic 
organisms of distantly related phylogenetic groups retain residues of the allosteric activator 
site, and in those instances where data are available, exhibit activation by phospho-
enolpyruvate.  Findings here unify disparate observations regarding bacterial FBPases, 
implicating a mechanism of feed-forward activation in bacterial central metabolism. 
 
Introduction 
Fructose-1,6-bisphosphatase (D-fructose-1,6-bisphosphate 1-phosphohydrolase, EC 
3.1.3.11; FBPase1) hydrolyzes fructose 1,6-bisphosphate (Fru-1,6-P2) to fructose 6-phosphate 
(Fru-6-P) and inorganic phosphate (Pi) (1, 2), and is a principal regulatory enzyme in 
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gluconeogenesis (1, 2).  With few exceptions, FBPase exists in nearly all organisms (2) and, 
at some level, in nearly all tissues (3).  Mammalian FBPases are tetrameric and adopt distinct 
quaternary states.  In the absence of AMP, the enzyme is in an active R-state conformation, 
whereas the AMP-bound form assumes an inactive T-state that differs from the R-state by a 
15o rotation between “top” and “bottom” subunit pairs (4-7).  In principle, hormonal control 
of levels of fructose 2,6-bisphosphate (Fru-2,6-P2), a potent inhibitor of FBPase in mammals, 
determines flux through the gluconeogenic pathway (8, 9).  Little is known, however, 
regarding the regulation of FBPases in prokaryotes, organisms that lack Fru-2,6-P2. 
Prokaryotic organisms express a diverse group of FBPases, classified by levels of 
sequence homology.  The Type I enzyme, which is the subject of this investigation, is the 
most widely distributed among living organisms, being the primary FBPase in Escherichia 
coli, most bacteria, a few Archaea, and all eukaryotic organisms known to possess the 
gluconeogenic pathway (10-14).  Many bacteria also express a second kind of FBPase (Type 
II), which in E. coli is encoded by the glpX gene (13).  The physiological role of the Type II 
enzyme in E. coli is unclear, but it may be the principal FBPase in other organisms (13, 15, 
16).  Some organisms of the phyla Firmicutes and Fusobacteria, and several of the class 
Bacteroidetes, also possess a third kind of FBPase (Type III), whereas Type IV FBPase is 
prevalent in Archaea, and Type V enzymes in thermophilic Archaea and at least one 
hyperthermophilic bacterium (17-19). 
Type I FBPase in E. coli most likely generates anabolic precursors for nucleotide, 
polysaccharide, and aromatic amino acid biosynthesis from gluconeogenic substrates (10, 
11).  Fructose-6-phosphate-1-kinase (PFK) and FBPase define a futile cycle (20).  Fraenkel 
and Horecker, who originally identified the enzyme in E. coli, reported the constitutive 
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expression of FBPase under all growth conditions and suggested the need for a mechanism of 
metabolic control (10).  Subsequent studies of FBPases in bacteria demonstrated only 2- to 3-
fold variations in enzyme levels under different conditions of growth (10, 21, 22).  Futile 
cycling, nonetheless, is minimal under both glycolytic (23) and gluconeogenic (24) growth 
conditions.  AMP is the only known physiological inhibitor of E. coli FBPase (25); however, 
AMP levels remain relatively constant under all growth conditions (26).  Additionally, an E. 
coli strain, deficient in wild-type FBPase, but complemented with an AMP-insensitive 
mutant of FBPase, exhibits normal growth (25).  Hence, AMP is an unlikely dynamic 
regulator of E. coli FBPase in vivo.  Phosphoenolpyruvate (PEP) on the other hand, relieves 
AMP inhibition (27, 28) and could be a physiological activator of FBPase in E. coli (14, 27).  
PEP activates the Type I enzyme from thermophilic bacterium Flavobacterium thermophilum 
HB8 (29), and the non-homologous Type II and Type III enzymes from E. coli (13) and the 
genus Bacillus (30, 31).  Prior to our previous investigation (14), the only proposed 
mechanism for PEP activation was the possible competition between PEP and AMP for a 
common site on the Type III enzyme from Bacillus licheniformis (30). 
The first crystal structure of an FBPase from Bacteria revealed several bound sulfate 
anions, one of which at a putative site of allosteric activation (14).  New conditions of crystal 
growth have resulted here in structure determinations of E. coli FBPase with bound PEP and 
with bound citrate.  These structures confirm the site of allosteric activation implied by the 
ligation of sulfate.  Unlike AMP, PEP concentrations in bacteria can fluctuate by more than 
10-fold between glycolytic and gluconeogenic conditions of growth (32).  Variations in PEP 
concentration could be the basis of coordinate regulation of FBPase and PFK, as PEP is also 
an inhibitor of the latter enzyme (33).  We report the direct activation of E. coli FBPase by 
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PEP, citrate, and similar metabolites, providing strong evidence of feed-forward activation of 
gluconeogenesis in bacteria belonging to distinct phylogenetic groups.  PEP and citrate may 
activate these bacterial FBPases directly by stabilizing the R-state tetramer and indirectly by 
blocking the AMP pocket via the insertion of a conserved aromatic side chain (Phe15).  On 
the basis of sequence conservation, the anion activation site is present in FBPases from a 
variety of organisms, including distantly related Flavobacteria.  FBPases from organisms 
within this class should be activated by PEP, a prediction supported by the literature (29).  A 
consensus sequence for the allosteric activator site suggests a widespread mechanism of 
regulation in central metabolism in bacteria and other microbes. 
 
Experimental: Materials and Methods 
Materials— Fru-1,6-P2, Fru-2,6-P2, NADP+, oxaloacetate, cis-aconitate, and α-
glycerophosphate came from Sigma.  PEP, glyceraldehyde 3-phosphate, fumarate, and 
malate came from MP biomedicals.  Glucose-6-phosphate dehydrogenase and 
phosphoglucose isomerase were from Roche Applied Sciences.  All other chemicals were of 
reagent grade or equivalent. 
Crystallization of R-state complexes— Native and selenomethionine-substituted 
proteins were prepared as previously described (14).  Crystals were grown by hanging drop 
in vapor diffusion VDX-plates (Hampton Research).  PEP-bound crystals grew from droplets 
containing 2 µL of a protein solution (15 mg/mL of selenomethionine-substituted FBPase, 20 
mM dithiothreitol, 0.2 mM EDTA, 5 mM Fru-1,6-P2, 5 mM MgCl2, and 10 mM PEP) and 2 
µL of a precipitant solution (50 mM sodium acetate, pH 5.6, 16% (w/v) PEG 1500, and 20% 
(w/v) sucrose) and were equilibrated over 500 µL of precipitant solution.  Citrate-bound 
 48 
   
 
crystals were grown similarly using the same protein solution (without PEP) and a precipitant 
solution containing 50 mM sodium citrate pH 5.3, 20% (w/v) PEG 3350, and 20% (w/v) 
sucrose.  Equal-dimensional crystals (0.2–0.3 mm) grew within 3 days at 22 °C under each of 
the conditions. 
Data Collection— Crystals were frozen directly in a cold stream of nitrogen without 
additional cyroprotectants.  Data were collected at Iowa State University on a Rigaku R-
AXIS IV++ rotating anode/image plate system using CuKα radiation from an Osmic confocal 
optics system at a temperature of 110 K.  The program d*trek (34) was used to index, 
integrate, scale and merge intensities, which were then converted to structure factors using 
the CCP4 (35) program TRUNCATE (36). 
Structure Determination and Refinement— A molecular replacement solution was 
obtained from the program AMORE (37) using a single subunit from sulfate-bound E. coli 
FBPase (PDB accession identifier 2GQ1), from which all ligand and water molecules had 
been removed.  Manual adjustments in the conformation of specific residues employed the 
program XTALVIEW (38).  The resulting model underwent simulated annealing from 3000 
to 300 K in steps of 25 K, followed by 100 cycles of energy minimization and thermal 
parameter refinement using CNS (39).  Force constants and parameters of stereochemistry 
were from Engh and Huber (40).  Restraints for thermal parameter refinement were as 
follows: 1.5 Å2 for bonded main-chain atoms, 2.0 Å2 for angle main-chain atoms and angle 
side-chain atoms, and 2.5 Å2 for angle side-chain atoms.  Ligands (fructose 6-phosphate and 
PEP or citrate) and water molecules were fit to omit electron density until no improvement in 
Rfree was evident.  Water molecules with thermal parameters above 50 Å2 or more than 3.2 Å 
from the nearest hydrogen bonding partner were removed from the final model. 
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Structure and sequence comparisons of FBPases— Dimer and tetramer models of 
FBPase were constructed from single subunits and used in pair-wise least-squares 
superpositions between E. coli and porcine liver enzymes using the CCP4 programs 
PDBSET (41) and LSQKAB (42).  Individual displacements between Cα positions in 
structures were measured using XTALVIEW (38).  The canonical R- and T-states of porcine 
FBPase used in superpositions have PDB identifiers 1CNQ and 1EYK, respectively, whereas 
the IT- and IR-states have identifiers 1Q9D and 1YYZ, respectively.  As the angle of rotation 
between subunit pairs in various quaternary states of FBPases is sensitive to the subset of 
residues employed in the least-squares fit, the previously established residues used to 
compare E. coli and porcine FBPases were used for all alignments (14).  Multiple sequence 
alignments of Type I FBPases employed the program CLUSTALW (43).  Optimal global 
pair-wise alignments, which served as the basis for calculating sequence identity, utilized the 
program ALIGN (44). 
Kinetic Experiments— Assays for FBPase activity employed the coupling enzymes 
phosphoglucose isomerase and glucose-6-phosphate dehydrogenase and monitored formation 
of NADPH by either absorbance at 340 nm or fluorescence emission at 470 nm (7).  
Coupling enzymes were dialyzed against a 1000-fold volume of 50 mM Hepes, pH 7.5, to 
remove ammonium sulfate that would otherwise be present at ~3 mM in all assays.  Assays 
(total volume, 2 mL) were performed at 22 °C in 50 mM Hepes, pH 7.5, with 100 µM EDTA 
and 150 µM NADP+.  Saturating levels of Fru-1,6-P2 (40 µM) and MgCl2 (10 mM) were used 
to measure specific activity and anion activation effects.  Assays were initiated by the 
addition of 1.4 µg enzyme (enzyme-initiated assays) or by incubating the enzyme in assay 
mixtures for 1–2 hr. at 22 °C without MgCl2, and subsequently initiating the reaction by the 
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addition of metal (enzyme-incubation assays).  Equations (indicated in figure legends) were 
fit to kinetic data using the program IGORPRO (WaveMetrics). 
Dynamic Light Scattering— Experiments were performed in the assay buffer, without 
coupling enzymes and Mg2+.  Samples of E. coli FBPase with subunit concentrations of 1, 2, 
3, 5, 8, and 14 µM were incubated in the presence and absence of 5 mM PEP for 2 hrs. prior 
to light scattering measurements at 22 °C.  Data were collected in 1 second intervals 
subdivided into 10 s acquisitions on a Protein Solutions DynaPro dynamic light scattering 
instrument.  Instrumentation software (DYNAMICS V6) facilitated the determination of 
diffusion coefficients from time correlation curves and the use of such data in the estimation 
of molecular masses. 
Estimation of metabolite concentrations in E. coli— Amounts of metabolites are often 
reported in units of mol/g dry weight of bacteria and may be converted to concentrations 
subject to several assumptions: the cytoplasm is homogenous, the cytoplasmic volume is the 
free-solution volume of the metabolite, and the total concentration of metabolite is its free 
concentration.  At an optimal osmolarity of 0.28OSM, Cayley et al. (45) determined a 
cytoplasmic volume of 2.08±0.06x10–6 L/mg of dry weight of bacteria.  Division by this 
value converts mol/g dry weight of bacteria to molar concentration. 
 
Results 
Enzyme Purity— Native and selenomethionine-substituted enzymes are kinetically 
and structurally indistinguishable (14).  Preparations of enzyme here give specific activities 
of 35–40 U/mg, appear as single bands on SDS-polyacrylamide gel electrophoresis (purity 
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level of at least 95%), and have a single residue type (methionine or selenenomethionine) at 
the N-terminus. 
Time-dependent Loss of E. coli FBPase Activity— Activity of E. coli FBPase 
diminishes upon dilution into assay buffers (FIGURE ONE).  Relative activity falls to ~70% 
after 2 minutes and reaches a threshold of ~35% after one hour.  Similar results occur in the 
presence or absence of substrate (40 µM Fru-1,6-P2), reducing agents (5 mM dithiothreitol or 
β-mercaptoethanol), glycerol, salts (20 mM NaCl, KCl, NH4Cl, or NaC2H3O2), and several 
buffers (50 mM Tris-malonate, Hepes-NaOH, Tris-HCl, or MES-NaOH).  Inorganic sulfates 
(20 mM Na2SO4, K2SO4, or (NH4)2SO4), and to a lesser extent inorganic phosphates 
(KH2PO4 or NaH2PO4), reduce activity loss.  5 mM PEP or citrate prevents time-dependent 
loss of activity, while decreasing relative activity by ~20% (FIGURE ONE).  On the other hand, 
5 µM AMP increases the rate of activity loss, reaching a threshold value of ~15% relative 
activity.  By way of comparison, relative activity is ~70% in the presence of 5 µM AMP in 
enzyme-initiated assays.  5 mM PEP (FIGURE ONE) or citrate (not shown) blocks the effects 
of 5 µM AMP.  In contrast to the E. coli enzyme, dilution and PEP have no discernable effect 
on the activity of porcine FBPase (FIGURE ONE).  Even after incubation in the assay buffer 
for 4 hours at 22 °C, porcine FBPase retains full activity. 
Variation of Kinetic Parameters with Assay Protocol— Kinetic parameters for E. coli 
FBPase, determined in the absence of PEP, differ for assays initiated by the addition of 
enzyme (no incubation) and initiated by the addition of Mg2+ after incubation of the enzyme 
under conditions of assay (TABLE ONE).  Incubation of enzyme for 1 hr. prior to initiation 
increases the Km for Fru-1,6-P2, and the Ka for Mg2+, and decreases kcat.  AMP inhibition, 
cooperative in enzyme-initiated assays (Hill coefficient, ~1.7), increases dramatically in  
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FIGURE ONE.  Time-dependent loss of E. coli FBPase activity.  Recombinant porcine and E. coli 
FBPases were diluted into the standard assay mixture (see Experimental section) without Mg2+ and 
then initiated by the addition of Mg2+ at various times after dilution.  Porcine FBPase (○) is stable 
under these conditions while E. coli FBPase ( ) exhibits partial loss of activity.  The addition of 5 
µM AMP (■) accelerates activity loss of E. coli FBPase, whereas the inclusion of 5 mM PEP (●) 
abolishes the effect, while causing weak (~20%) inhibition.  The effect of 5 mM PEP and 5 µM AMP 
(▲) is indistinguishable from that of 5 mM PEP.  The effects of citrate are analogous to those of PEP 
(data not shown). 
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TABLE ONE.  Kinetic parameters for wild-type E. coli and porcine FBPases.  See Experimental 
section for specific conditions of assay. 
 
Enzyme kcat (s-1) 
Km Fru-1,6-P2 
(µM) 
Ka Mg2+ 
(mM) Hill Mg
2+ I0.5 AMP (µM) Hill AMP 
E. colia 24 ± 3 1.7 ± 0.1 1.0 ± 0.1 1.0 ± 0.1 18.1 ± 0.5 1.67 ± 0.08 
E. coli b 8 ± 1 16 ± 4 1.8 ± 0.1 1.3 ± 0.1 2.2 ± 0.1 0.82 ± 0.03 
E. colic 26 ± 3 1.4 ± 0.2 0.75 ± 0.05 1.0 ± 0.1 20 ± 1 2.0 ± 0.2 
Porcine liverd 22 ± 1 1.8 ± 0.1 0.82 ± 0.05 1.9 ± 0.1 1.61 ± 0.05 2.2 ± 0.1 
 
TABLE ONE.  Footnotes. 
 
aAssays initiated by the addition of enzyme. 
bEnzyme incubated for 1hr. in assay mixture.  Reaction initiated by the addition of Mg2+. 
cAssay mixtures contain 1 mM PEP.  Enzyme incubated for 1hr. in assay mixture.  Reaction initiated 
by the addition of Mg2+. 
dParameters previously reported (7, 57) and are independent of the method of assay. 
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incubation assays, and is non-cooperative (Hill coefficient, ~0.8).  Kinetic parameters from 
incubation assays that include 1 mM PEP, however, are similar to those of enzyme-initiated 
assays (TABLE ONE). 
Metabolic Activators of E. coli FBPase— Activation by citrate, PEP and other 
effectors is evident only in incubation assays.  In enzyme-initiated assays, 1 mM PEP has 
little effect.  PEP (or citrate) concentrations of 1–5 mM weakly inhibit enzyme activity, but 
inhibition is small relative to the magnitude of activation attributed to these ligands in 
incubation assays. 
Incubation of E. coli FBPase for 2 hours (see EXPERIMENTAL section for specific 
conditions) individually with intermediates of the TCA cycle or three-carbon intermediates 
of glycolysis, increase relative activity by as much as 500% (FIGURE TWO).  PEP, citrate, 3-
phosphoglycerate, cis-aconitate, isocitrate, oxaloacetate and α-ketoglutarate enhance enzyme 
activity at concentrations up to 5 mM.  PEP is the most potent activator, achieving nearly full 
activation at ~50 µM.  Citrate exhibits maximal activation comparable to PEP at a 
concentration of ~1 mM.  Relative velocity increases hyperbolically with the concentration 
of PEP and citrate (FIGURE TWO), with 50% of maximum activation (A0.5) coming at 27±2 
and 210±10 µM, respectively.  Concentrations of 10 mM malate or fumarate exhibit weak 
activation (data not shown). 
PEP and citrate are antagonists of AMP inhibition (TABLE ONE).  The concentration 
of AMP causing 50% inhibition (I0.5) in incubation assays is 2.2 µM, but in the presence of 
40 µM, 1 mM, and 2 mM PEP increases to 6.1, 20, and 44 µM, respectively.  The nonlinear 
variation of I0.5 for AMP with the concentration of PEP probably stems from cooperativity in 
AMP binding and/or changes in the quaternary state of the enzyme.  Citrate (2 mM) increases  
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FIGURE TWO.  Activation of E. coli FBPase by intermediates of glycolysis and the TCA cycle.  
(A) Recombinant E. coli FBPase was incubated with the standard assay mixture (see Experimental 
section) supplemented with ligands at concentrations of 50, 1000, or 5000 µM, corresponding to 
black, light grey, and white bars, respectively.  Assay mixtures were incubated 2 hr. at 22 oC prior to 
the addition of MgCl2.  Bar heights are the mean of three independent assays, indicating percent 
activity relative to a control with no additional ligand.  Error bars represent ±1σ deviation.  (B) 
Concentration dependence of activation exhibited by PEP ( ), citrate (■), and PEP in the presence of 
40 µM AMP (▲).  Error bars represent ±1σ deviation from data of three separate determinations.  
Curves come from a fit of the relationship v = v0 + (Vmax–v0)*[A]/(A0.5+[A]) to the data, where v is the 
observed velocity, v0 the velocity in the absence of activator, Vmax the limiting velocity, [A] the 
concentration of activator, and A0.5 the concentration of effector that results in a velocity of 
½(Vmax+v0), or 50% activation.  In the absence of AMP, A0.5 values for PEP and citrate are 27±2 and 
210±10 µM, respectively.  In the presence of 40 µM AMP, A0.5 for PEP is 1.4±0.2 mM. 
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the I0.5 for AMP to 10 µM.  As illustrated in FIGURE ONE, 5 µM AMP causes no measurable 
inhibition in the presence of 5 mM PEP (or citrate, not shown).  Alternatively, the A0.5 for 
PEP is 27±2 µM in the absence of AMP and increases to 1.4±0.2 mM in the presence of 40 
µM AMP.  In contrast to the E. coli enzyme, PEP (2 mM) has no effect on AMP inhibition in 
porcine FBPase. 
R-state structures of E. coli FBPase— R-state crystals of E. coli FBPase belong to the 
space group I222 for both PEP-bound (a = 44.7, b = 83.1, c = 174.4 Å) and citrate-bound (a 
= 45.3, b = 83.3, c = 173.4 Å) structures, and are isomorphous to crystals of the E. coli 
enzyme grown in the presence of high concentrations of sulfate (14, PDB identifier 2GQ1).  
Statistics of data collection and refinement are listed in TABLE TWO.  Unit cell parameters 
here and for crystals of the sulfate-ligated enzyme differ by less than 3%.  The models for the 
PEP and citrate complexes are complete except for some residues of the dynamic loop 
(residues 46–62), for which there is no interpretable electron density.  Electron density is 
present for a molecule of Fru-6-P, bound to the active site, but no density appears for 
inorganic phosphate or Mg2+.  Disorder in the dynamic loop may stem from the absence of 
bound metal and phosphate.  The absence of bound phosphate and Mg2+ could be a 
consequence of low pH and/or non-saturating concentrations of metal ion and/or phosphate.  
One molecule of PEP or citrate binds per monomer to the same allosteric activator site 
(FIGURE THREE).  PEP and citrate bind to FBPase stoichiometrically with one water molecule 
and form extensive networks of hydrogen bonds between top (C1-C2) and bottom (C3-C4) 
dimers of E. coli FBPase (FIGURE FOUR).  Interactions between ligands and protein appear in 
TABLE THREE. 
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Table TWO.  Statistics of data collection and refinement of R-state complexes of E. coli FBPase.  
Space group and unit cell parameters are in the Results section.  Parenthetical values pertain to the 
highest resolution shell of data.  Ramachandran plots from PROCHECK (58) confirm good peptide 
geometry. Both models have >86% of residues in most favored regions and no residues in disallowed 
conformations. 
 
 PEP-bound (PDB ID 2OX3) 
Citrate-bound 
(PDB ID 2OWX) 
Resolution (Å) 75.03–2.18 (2.32–2.18) 43.84–2.18 (2.32–2.18) 
Total reflections/unique reflections 115,644/17,261 88,622/17,445 
Average redundancy 6.7 (6.0) 5.1 (4.4) 
% Completeness 98.7 (92.8) 98.9 (96.2) 
Rmergea 0.046 (0.238) 0.033 (0.205) 
I/σ(I) 21.1 (6.8) 22.7 (6.5) 
Number of atoms 2582 2579 
Number of solvent sites 80 74 
Rfactorb 21.2 20.8 
Rfreec 26.2 24.9 
Mean thermal parameters (Å2): 
Protein 39.5 44.1 
Fru-6-P 33.1 46.4 
PEP/citrate 41.8 43.3 
Root mean-squared deviations: 
   Bond lengths (Å) 0.006 0.006 
   Bond angles 1.2 1.2 
   Dihedral angles 22.5 22.2 
   Improper angles 0.8 0.7 
 
TABLE TWO.  Footnotes. 
 
aRmerge = ΣjΣi | Iij  – <Ij> | /ΣiΣjIij, where i runs over multiple observations of the same intensity and j 
runs over all the crystallographically unique intensities. 
bRfactor = Σ || Fobs | – | Fcalc || /Σ | Fobs |, where | Fobs | > 0 
cRfree is the Rfactor based upon 10% of the data randomly culled and not used in the refinement. 
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FIGURE THREE.  Overview of the R-state E. coli FBPase with bound PEP or citrate.  Fru-6-P 
binds to the active site, the side chain of Phe15 lies in the AMP pocket, and either PEP or citrate binds 
to the anion activation site at the C1-C4 subunit interface with a stoichiometry of four molecules per 
tetramer as shown.  Ligands are covered by electron density from Fo-Fc omit maps contoured at 3σ, 
using a cutoff radius of 2.0 Å.  Phe15 is covered by electron density from a map (2Fo-Fc) contoured at 
1σ.  This drawing was prepared with MOLSCRIPT (59). 
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FIGURE FOUR.  Ligated activation site of E. coli FBPase.  Citrate (left) and PEP (right) hydrogen 
bond extensively across the C1-C4 interface.  Dotted lines are donor-acceptor interactions of 3.2 Å or 
less, with a complete list of such interactions appearing in TABLE THREE.  Interactions with the 
backbone amide group of Phe187 are omitted for clarity.  The tetramer icon illustrates the viewing 
direction and region.  This drawing was prepared with MOLSCRIPT (59). 
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TABLE THREE.  Selected donor-acceptor interactions of bound ligands.  Atom names correspond 
to those in FIGURE FIVE.  Residues from a symmetry-related subunit are marked with an asterisk. 
 
Ligand Group & Atom Bonding Partner Distance (Å) 
Citrate/Wat733: 
1-carboxyl O1 Lys30 NZ 2.71 
 Gly5 N 2.88 
1-carboxyl O2 Phe187 N 2.79 
 Wat733 2.81 
2-carboxyl O5 Thr3 OG 2.65 
 Arg80 NH2* 2.55 
2-carboxyl O6 Arg80 NH1* 2.93 
3-carboxyl O3 Lys34 NZ* 2.65 
3-carboxyl O4 Wat733* 2.85 
2-hydroxyl O7 Lys30 NZ 2.97 
Wat733 O Lys34 NZ 2.60 
PEP/Wat541: 
2-phosphoryl O1P Arg80 NH2* 2.60 
 Thr3 OG 2.56 
2-phosphoryl O2P Gly5 N 2.60 
 Wat541 2.95 
2-phosphoester O3 Lys30 NZ 2.99 
 Wat541  2.85 
1-carboxyl O1 Lys34 NZ* 2.69 
1-carboxyl O2 Lys34 NZ* 2.79 
Wat541 O Lys30 NZ 2.81 
 Phe187 N 2.94 
Fru-6-P: 
1-hydroxl O1 Glu275 OE1 2.63 
3-hydroxl O3 Asp113 OD2 2.61 
 Leu243 N 2.89 
4-hydroxl O4 Wat527 2.74 
 Tyr257 OH 2.61 
2,5-ether O5 Lys269 NZ 2.87 
6-phosphoester O6 Lys269 NZ 3.15 
6-phosphoryl O61 Arg238 NH2* 2.86 
6-phosphoryl O62 Tyr259 OH 2.56 
 Wat506  2.63 
 Wat542 2.73 
6-phosphoryl O63 Arg238 NH1* 3.14 
 Asn206 ND2 2.74 
 Tyr239 OH 2.82 
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The PEP- and citrate-bound structures exhibit no differences beyond coordinate error, 
differing principally by the bound ligand.  The quaternary states of the citrate and PEP 
complexes of the E. coli enzyme match the canonical R-state of porcine FBPase on the basis 
of tetramer superpositions.  (The rotation angle between subunits pairs C1-C2 and C3-C4 
differ by no more than 0.1° in any superposition).  By way of comparison, the rotation angle 
between subunit pairs C1-C2 and C3-C4 of the sulfate complex of the E. coli FBPase is 6.0° 
away from the canonical R-state and toward the T-state.  The side chain of Phe15 occupies the 
AMP pocket in the PEP and citrate complexes as it does in the sulfate complex (14).  The 
tertiary structures of mammalian and E. coli enzymes are nearly identical on the basis of Cα 
traces (FIGURE FIVE), differing mainly in loop regions connecting secondary structural 
elements. 
Dynamic Light Scattering— Native mass determinations using E. coli FBPase subunit 
concentrations of 1–14 µM and 5 mM PEP were substantially larger (122±4 kDa) than 
corresponding determinations made in the absence of PEP (70±15 kDa).  Mass 
determinations varied little with protein concentration, suggesting the existence of 
homogenous states in the presence and absence of PEP that differ in subunit association, such 
as a tetramer (calculated mass ~147 kDa) in the presence of PEP and a dimer (calculated 
mass ~74 kDa) in its absence.  The dissociation constant for a tetramer to dimer equilibrium 
must be no higher than 10–7 M in the presence of PEP and no lower that 10–5 M in the 
absence of PEP. 
Identification of Organisms Possessing Anion-Activated FBPase— Five residues 
signify the probable existence of anion activation in FBPase.  Gly5, Lys30, and Arg80 bind 
directly to the activator, Phe15 blocks the AMP pocket and Val186 (in place of glutamate in  
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FIGURE FIVE. Superposition of R-state subunits from E. coli and mammalian FBPases.  Cα atoms 
from the E. coli subunit are connected sequentially by solid lines and those of the porcine subunit by 
dashed lines.  Fru-6-P and PEP (bold lines) and residue numbers are from E. coli FBPase.  Subunit 
orientation corresponds to that of subunit C2 of FIGURE THREE.  Structural differences occur at N- 
and C-termini and in some loops.  This drawing was prepared with XTALVIEW (38). 
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FBPases from eukaryotic organisms) makes room for the anion to bind at the C1-C4 interface 
(See FIGURE THREE for definition of subunit interfaces).  The five signature residues are 
present in FBPase from known heterotrophic bacteria.  With little exception, these residues 
appear in an all-or-none fashion, defining a consensus sequence (TABLE FOUR) linked to 
allosteric activation of gluconeogenesis.  Alignments of sequences (>100) in previous work 
(14), expanded here to include >250 sequences, identifies 44 species having a Type I FBPase 
with the potential for allosteric activation.  Excluding the sole eukaryote, the protozoan 
parasite Toxoplasma gondii, these organisms are all members of the domain Bacteria and 
separate into two phyla.  The majority belong to the phylum Proteobacteria, class 
Gammaproteobacteria, and occupy the orders Enterobacteriales, Alteromonadales, 
Vibrionales, Pasteurellales, Reinekea, and Oceanospirillales.  A second group occupies the 
phylum Bacteroidetes and the class Flavobacteria. 
 
Discussion 
Results here unify many disparate observations reported by investigators of bacterial 
FBPases.  E. coli FBPase undergoes a time-dependent change upon dilution (11, 27), a 
phenomenon originally attributed to an effect of the substrate in assay buffers (11).  Past 
investigators initiated assays with enzyme (11, 27, 28, 46), but in so doing minimized the 
influence of anionic ligands on enzyme activity.  Differences in assay protocols and the 
uncontrolled presence of activating anions, such as sulfate, can account for significant 
variations in kcat, Km, and cooperativity in AMP inhibition (TABLE ONE).  For instance, Hill 
coefficients for AMP inhibition range from 1.1–3.2 in the literature (28, 46) and from 0.8–2.6 
in the present study. 
 64 
   
 
 
 
TABLE FOUR.  Consensus residue types indicative of allosteric activation in FBPases of 44 
species.  Type-I FBPase sequence alignments from more than 250 species of eukaryotes and bacteria 
produced a consensus sequence and list of organisms which possess an anion-activated FBPase.  
Species with consensus residue types are as follows: E. coli, Shigella flexneri, Shigella sonnei, 
Salmonella typhimurium, Salmonella paratyphi-a, Salmonella choleraesuis, Salmonella typhi, 
Erwinia carotova, Sodalis glossinidius, Photorhabdus luminescens, Yersinia pseudotuberculosis, 
Yersinia frederiksenii, Yersinia mollaretii, Yersinia intermedia, Vibrio cholerae, Yersinia 
pestis,Vibrio angustum, Vibrio vulnificus, Vibrio splendidus, Vibrio parahaemolyticus, 
Photobacterium sp. SKA34, Photobacterium profundum, Vibrio fischeri, Haemophilus somnus, 
Reinekea sp. MED29 7, Psychromonas sp. CNPT3, Haemophilus influenzae, Vibrio alginolyticus, 
Pasteurella multocida, Mannheimia succiniciproducens, Hahella chejuensis, Actinobacillus 
pleuropneumoniae, Haemophilus ducreyi, Robiginitalea biformata, Flavobacteriales bacterium 
HTCC2170, Croceibacter atlanticus HTCC2559, Flavobacteria bacterium BBFL7, Tenacibaculum 
sp. MED152, Cellulophaga sp. MED134, Flavobacterium johnsoniae, Polaribacter irgensii 23-P, 
Flavobacterium sp. MED217, Psychroflexus torques, Toxoplasma gondii.  All species are obligate 
heterotrophs, many are pathogenic, and all but one (T. gondii) are bacteria.  Overall sequence identity 
to E. coli FBPase varies from 52–100%.  P. irgensii 23-P has two isozymes of Type-I FBPase with 
sequence identities of 57 and 61% to E. coli FBPase. 
 
Sequence 
position in 
E. coli 
FBPase 
Consensus 
residue type 
 
Exceptions 
 
5 Gly H. influenzae (Ser) M. succiniciproducens (Asp) 
15 Phe/Tyr T. gondii (Leu) 
30 Lys/Arg none 
80 Arg none 
186 Val/Thr/Ser A. pleuropneumoniae (Leu) Reinekea sp. MED297 (Ile) 
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Dilution-linked loss of FBPase activity stems from a conformational change in the 
tetramer or from the dissociation of the tetramer into subunit monomers and/or dimers.  
Variation in the native mass of E. coli FBPase in the presence and absence of PEP would  
provide direct evidence in favor of the latter; however, the lowest reachable subunit 
concentration in dynamic light scattering measurements (~1 µM) is 50-fold higher than the 
subunit concentration of FBPase in assays (~20 nM).  Nonetheless in the absence of an 
activator, light scattering data indicate a native mass for E. coli FBPase in the range of a 
subunit dimer (observed, 70±15 kDa, expected, 74 kDa), whereas the native mass of the 
enzyme in the presence of 2 mM PEP is near that of the tetramer. 
The subunits of the putative dimer could be related by the C1-C4 interface or the C1-
C2 interface, but the latter is more likely.  Ligands perturb the C1-C4 interface as evidenced 
by the rotation angles for C1-C2 subunit pairs in the PEP and citrate complexes (rotation 
angle of 0°) and the sulfate complex (rotation angle of 6°).  In the absence of anionic ligands, 
the C1-C4 subunit interface would have a net positive charge (14).  Finally, porcine FBPase 
requires functional AMP sites in the top (C1-C2) and bottom (C3-C4) halves of the tetramer 
for cooperativity in AMP inhibition (47), and mutations to residues that facilitate interactions 
across the C1-C4 interface eliminate AMP cooperativity (6, 48).  By analogy, a C1-C2 dimer 
of E. coli FBPase, should exhibit noncooperative inhibition by AMP, and in fact, AMP 
inhibition in enzyme-incubated assays in the absence of PEP is without cooperativity (TABLE 
ONE).  All data then are consistent with the complete dissociation of the E. coli tetramer into 
less active C1-C2 subunit dimers under conditions of low protein concentration and in the 
absence of anion activators. 
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An initial study revealed sulfate and PEP as activators of E. coli FBPase (14); 
however, anion activation is widely shared by metabolites of central metabolism.  In fact, a 
high formal negative charge is the principal attribute common to all activators of E. coli 
FBPase.  PEP and citrate, for instance, are structurally dissimilar, but have a formal charge at 
or near –3 at neutral pH.  Other potent activators are either phosphorylated carboxylic acids 
(PEP-like) or tricarboxylic acids (citrate-like).  3-Phosphoglycerate, cis-aconitate, and 
isocitrate, exhibiting maximal activation at concentrations of 1 mM, probably form 
interactions with the protein similar to those of PEP or citrate.  2-Phosphoglycerate (not 
tested) is probably an activator, being similar to PEP and 3-phosphoglycerate in charge and 
structure.  Oxaloacetate, α-ketoglutarate, malate, fumarate, sulfate, and phosphate with a 
formal charge at or near –2 at neutral pH act only at elevated concentrations.  Indeed at pH 
7.5, sulfate is a dianion, whereas phosphate is an equilibrium mixture of di- and mono-
anions, which may explain the superior activating effect of sulfate relative to phosphate (14).  
Activation by oxaloacetate and α-ketoglutarate at concentrations of 5 mM, and by malate and 
fumarate at concentrations of 10 mM are probably unimportant physiologically.  For the 
latter pair, observed activation could arise from as little as a 0.5% contamination by citrate. 
Structures of the PEP- and citrate-bound FBPases reveal the mechanism by which the 
same effector site can recognize different ligands.  In one sense, the activator site recognizes 
neither PEP nor citrate, but rather hydrated forms of each ligand (FIGURE FOUR).  In the PEP 
complex, a water molecule occupies the position of an oxygen atom of the 1-carboxyl group 
of citrate, and in the citrate complex, a water molecule is near the position of an oxygen atom 
of the carboxyl group of PEP (FIGURE SIX).  These water molecules satisfy hydrogen bonds 
with the protein that the ligand itself cannot make.  Moreover, the water molecules act as  
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FIGURE SIX.  Superposition of bound PEP and citrate molecules.  The superposition of PEP (bold 
lines) and citrate is based on the Cα atoms of the PEP- and citrate-bound tetramers.  Single water 
molecules (octahedral crosses) combine with PEP and citrate to complement the interactions of each 
effector.  This drawing was prepared with MOLSCRIPT (59). 
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caulks, filling potential voids and taking advantage of hydrogen bonds and favorable non-
bonded interactions with the protein and ligand.  The loss of a single oxygen atom (the 
absence of a single water molecule, for instance) can increase ligand dissociation constants 
by 40-fold (49).  Hence, water molecules that bind with PEP and citrate are probably critical 
determinants in the thermodynamic stability of these ligand-enzyme complexes. 
The difference in quaternary conformation (6° rotation of subunit pairs) between the 
sulfate and PEP (or citrate) complexes may stem from different interactions of the sulfate 
anion (SO4344, 14) relative to citrate and PEP.  The sulfate anion at the activator site (SO4344 
in reference 14), the phosphoryl group of PEP and one oxygen atom of the 1-carboxyl group 
and both oxygen atoms of the 2-carboxyl group of citrate occupy the same volume of space.  
What differs conspicuously is the absence of a sulfate interaction that corresponds with the 
hydrogen bond between Lys34 and the carboxyl group of PEP or the 3-carboxyl group of 
citrate.  The PEP/citrate hydrogen bond to Lys34 spans the C1-C4 interface and may rotate 
subunit pairs into their eclipsed relationship of the canonical R-state. 
Alternatively, the different quaternary state of the sulfate-ligated complex may stem 
from the presence of an additional sulfate anion.  Superpositions of single subunits of the 
sulfate, PEP and citrate complexes localize the largest change in tertiary conformation 
(displacements of approximately 1 Å) to the C-terminal end of helix H2 near the center of the 
tetramer (FIGURE SEVEN).  A sulfate anion (SO4341 in reference 14) on the C1-C2 molecular 
twofold axis interacts with the side chains of Arg38 and His37, and conformational changes in 
these side chains correlate with rigid-body movements of helix H2.  The quaternary state of 
the sulfate complex then may be due to SO4341, which may bind to the enzyme by virtue of its 
elevated concentration (~1 M) in previous crystallization experiments.  Synthetic inhibitors  
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FIGURE SEVEN.  Tertiary conformational changes of helix H2 correlated with the presence of 
sulfate.  The area near the sulfate anion at the C1-C2 interface and the C-terminus of helix H2 is 
enlarged. The superposition of single subunits of the PEP- and sulfate-bound structures reveals an 8 Å 
movement in the side chain of Arg38 (illustrated by the arrow), hydrogen bonding internally with 
SO4341 (bold lines) near the center of the tetramer, but moving to a surface-exposed conformation in 
the PEP-bound structure.  Movement of Arg38 and the C-terminal end of helix H2 are correlated.  This 
drawing was prepared with MOLSCRIPT (59). 
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that bind to the center of porcine FBPase also stabilize an intermediate quaternary state (50).  
Whether these synthetic inhibitors of the mammalian enzyme and SO4341 of the E. coli 
enzyme mimic the interaction of a physiological effector at the center of the tetramer is 
unclear. 
The interaction of PEP/citrate with Lys34 in E. coli FBPase is structurally equivalent 
to the interactions of Glu192 with Lys42 of R-state porcine FBPase.  Hence, the porcine 
enzyme may represent evolution toward a permanently activated state of FBPase.  Basic 
residues (Lys30, Lys34, and Arg80) of the anion binding site of E. coli FBPase balance the 
electrostatic charge of the most potent anion activators (Figure FOUR).  The formal positive 
charge here is +1 for porcine FBPase, with Cys38 and Ser88 replacing Lys30 and Arg80, 
respectively.  In fact, Glu192 occupies the “anion site” in porcine FBPase, balancing the 
positive charge and making hydrogen bonds that bridge the C1-C4 interface.  Despite being 
vastly different from the porcine enzyme at the C1-C4 interface, and differing in residue type 
at 195 positions, E. coli and porcine FBPases adopt virtually identical R-states.  Evidently, 
the R-state tetramer of FBPase has been retained through evolution, and may be conserved in 
Bacteria and Metazoa. 
In principal, a decrease in PFK activity and a concomitant increase in FBPase activity 
would transform glycolytic into gluconeogenic flux.  The Fru regulon controls flux through 
PEP carboxykinase and PEP synthase by adjusting the expression levels of these enzymes 
(21, 51, 52); however, levels of FBPase and PFK change by only 2- to 3-fold on growth 
media of glucose versus acetate (21, 22).  Metabolite regulation of FBPase and PFK-1 in vivo 
then seems the only option, but such a mechanism requires coordinated changes in the 
concentrations of free AMP, PEP and citrate.  Estimates of AMP concentrations in vivo range 
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from 20–60 µM (26) to as high as 150 µM (27).  Although these estimates may be 
erroneously high due to the uncontrolled degradation of ADP and ATP, AMP levels are 
certainly 5-fold higher than the I0.5 value (~2 µM) for E. coli FBPase in the absence of an 
activating anion.  Hence, FBPase should be inactive if AMP were the only effector.  PEP 
concentrations, however, change from 50 to 1000 µM in E. coli between glycolytic and 
gluconeogenic conditions of growth, respectively.  The A0.5 values for PEP in the presence of 
either 0 or 40 µM AMP determined here are 27±2 µM and 1.4±0.2 mM, spanning the range 
of PEP concentrations found in E. coli.  Moreover, PEP also inhibits PFK in E. coli (33), and 
the in vitro behavior of PFK at physiological concentrations of substrates and effectors 
(including PEP) is consistent with a metabolite mechanism of regulation in vivo (53).  As a 
final consideration, changes in the concentration of PEP respond rapidly to changes in 
nutrients; PEP levels fall 70% within 3 minutes after the addition of glucose to a succinate 
growth medium (32).  All of these observations support the hypothesis of metabolite 
regulation of glycolysis and gluconeogenesis by the coupling of PFK and FBPase activities 
to the in vivo concentration of PEP. 
Organisms that have the potential for PEP regulation of gluconeogenesis via the 
bacterial anion activation site (see TABLE FOUR) exhibit several trends worth noting.  Many 
are free-living, opportunistic pathogens, and all are obligate heterotrophs, with the ability to 
use nutrients that enter glycolysis/gluconeogenesis above and below the FBPase/PFK step.  
The requirement for metabolite regulation of FBPase may stem from a need to adapt quickly 
to changes in nutrient availability, utilizing a variety of carbon sources for both energy and 
biochemical synthesis.  Absent from TABLE FOUR are lithotrophs, phototrophs, and 
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autotrophs; these organisms likely run their glycolytic/gluconeogenic pathways uni-
directionally (predominantly anabolic). 
In some instances, the anion activation site of bacterial FBPases may be a potential 
target for anti-microbial agents.  The requirement for a functional FBPase in pathogenic 
organisms varies dramatically.  At one extreme, the protozoan parasite Plasmodium 
falciparum, the cause of malaria, no longer possesses the FBPase gene (among other 
gluconeogenic genes).  P. falciparum presumably uses glucose from the host for energy 
production and biochemical synthesis (54, 55).  In sharp contrast, FBPase activity in another 
protozoan, the parasite Leishmania major, which causes Leishmaniasis, is vital to 
pathogenesis (56).  The pathogenic protozoan, Toxoplasma gondii, the cause of 
toxoplasmosis, possesses a bacteria-like FBPase, but the relationship between FBPase 
activity and pathogenicity (if any) is unclear.  The accurate prediction of FBPase dependency 
of seemly related microorganisms is problematic, necessitating for the present, an 
experimental evaluation of each target. 
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Abstract 
Allosteric activation of fructose-1,6-bisphosphatase (FBPase) from Escherichia coli 
by phosphoenolpyruvate and citrate implies rapid feed-forward activation of gluconeogenesis 
in heterotrophic bacteria.  The question remains, however, as to the how such bacteria can 
rapidly down-regulate an activated FBPase in order to avoid futile cycling.  Demonstrated 
here is the allosteric inhibition of E. coli FBPase by glucose 6-phosphate (Glc-6-P), the first 
metabolite produced upon glucose transport into the cell.  Crystal structures reveal a 
transition from the canonical R-state to a T-like state in response to Glc-6-P and AMP 
ligation.  Both ligands bind to allosteric sites: AMP to a site comparable to that of 
mammalian FBPases and Glc-6-P to a site heretofore not observed in previous FBPase 
structures.  AMP displaces Phe15 and helix H1 toward the center of the tetramer by 3 Å, 
perturbing the allosteric activator site for phosphoenolpyruvate/citrate.  Kinetic data show 
synergistic inhibition of E. coli FBPase by Glc-6-P and AMP, placing AMP/Glc-6-P 
inhibition in bacteria as a possible evolutionary predecessor to AMP/fructose 2,6-
bisphosphate inhibition in mammalian FBPases.  Residues that bind Glc-6-P are present in 
organisms that possess key residues for allosteric activation.  FBPase in these organisms may 
act as a metabolic switch in response to intracellular concentrations of Glc-6-P or PEP, which 
vary dramatically with nutrient availability. 
 
Introduction 
Fructose-1,6-bisphosphatase (D-fructose-1,6-bisphosphate 1-phosphohydrolase, EC 
3.1.3.11; FBPase1) catalyzes the hydrolysis of fructose 1,6-bisphosphate (Fru-1,6-P2) to 
fructose 6-phosphate (Fru-6-P) and inorganic phosphate (Pi), and is a principal regulatory 
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enzyme in gluconeogenesis (1, 2).  Primary sequence comparisons infer five non-
homologous FBPases in living organisms.  All five types exist in various prokaryotes, but the 
Type I enzyme is the only form in eukaryotes (3-8).  In the enteric bacterium Escherichia 
coli, the Type I enzyme is absolutely required for growth on gluconeogenic substrates (3) and 
is subject to regulation by certain metabolites (4, 7-9).  Type I FBPases are tetrameric with 
subunits labeled C1–C4 by convention and adopt distinct quaternary states called R-, IT-, and 
T-, dependent upon ligation by effectors (10-14).  In crystal structures, the porcine liver 
enzyme takes on an active R-state conformation in the absence of the inhibitor AMP, 
whereas the AMP-bound form assumes an inactive T-state that differs from the R-state by a 
15o rotation between “top” and “bottom” subunit pairs (10-13).  The competitive inhibitor 
fructose-2,6-bisphosphate (Fru-2,6-P2) converts the enzyme to an intermediate state (IT) 
which lies 13o away from the R-state (14). 
The constitutive expression of both fructose-6-phosphate-1-kinase (also called 
phosphofructokinase or PFK) and FBPase in the bacterial cytosol demands a strategy of 
coordinate regulation to avoid futile cycling at the expense of ATP (3, 8, 15).  Expression 
levels of FBPase and PFK in E. coli vary only 2-3 fold between glycolytic and gluconeogenic 
conditions and yet futile cycling remains low under both conditions (16-19), indicating 
regulation at the metabolite/enzyme level.  Phosphoenolpyruvate (PEP) and citrate are 
probable in vivo allosteric effectors in the feed-forward activation of E. coli FBPase and 
gluconeogenesis (8).  Activators of E. coli FBPase bind to allosteric sites at the C1-C2/C3-C4 
dimer interface, stabilizing an R-state identical to the mammalian enzyme and antagonizing 
the binding of the inhibitor AMP (8).  Unlike AMP concentrations, which are relatively 
constant in vivo, the concentrations of PEP vary coordinately with the availability of non-
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glucose carbon sources, and hence PEP may adequately activate FBPase when such nutrients 
are available (20, 21).  But then how does E. coli respond rapidly to the sudden influx of 
glycolytic substrates like glucose?  Eukaryotic organisms have evolved the signal metabolite 
Fru-2,6-P2 to activate PFK and inhibit FBPase within the cytosol.  The budding yeast 
Saccharomyces cerevisiae, for instance, produces inhibitory levels of Fru-2,6-P2 within one 
minute of glucose exposure (22).  Currently, there is no known mechanism in heterotrophic 
bacteria such as E. coli for the rapid inhibition of FBPase in response to glucose influx. 
The position of FBPase near the end of the gluconeogenic pathway leaves only a few 
candidate metabolites as logical inhibitors.  Glucose is immediately phosphorylated to 
glucose 6-phosphate (Glc-6-P) upon transport into the bacterial cell via the action of either 
the PEP phosphotransferase system or glucokinase (23).  Glc-6-P levels vary as much as 10-
fold between E. coli grown on different carbon sources, and can rapidly fluctuate 5-7 fold in 
response to nutrient availability (21).  The position of Glc-6-P as a downstream product of 
the FBPase reaction, coupled with its dynamic variation in response to nutrients, makes it an 
ideal candidate for an inhibitor of FBPase.  A previous investigation, now nearly 40 years 
past, identified an E. coli mutant lacking both phosphoglucose isomerase and glucose-6-
phosphate dehydrogenase activity that accumulated large amounts of intracellular Glc-6-P 
(~50 mM, normal range 0.2–2 mM) (21, 24).  This mutant was unable to grow on certain 
gluconeogenic substrates, such as glycerol, even with supplemental glucose, indicating a 
linkage between growth deficiencies and the inhibition of FBPase by the abnormal levels of 
Glc-6-P (24).  In vitro assays of impure FBPase showed Glc-6-P inhibition with an I0.5 of 
nearly 10 mM, undermining the physiological relevance of such inhibition (24). 
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We demonstrate here, however, the inhibition of purified E. coli FBPase (specific 
activity 1000-fold higher than that used in the early investigation) at physiologically relevant 
concentrations of Glc-6-P.  Moreover, Glc-6-P enhances AMP inhibition by as much as 10-
fold, even in the presence of 1 mM PEP, a property which might allow Glc-6-P to override 
PEP activation of gluconeogenesis in the presence of glucose.  Glc-6-P binds to a distinct 
allosteric site never before observed in FBPase structures.  Heterotrophic bacteria that 
possess the allosteric activation site for PEP have residue types in common with those of the 
allosteric pocket that recognizes Glc-6-P (7, 8).  Structural evidence supports a model in 
which Glc-6-P and AMP bind to the enzyme and induce a transition to a T-like state, similar 
in rotation to the IT-state of the mammalian enzyme.  AMP displaces the side-chain of Phe15 
from its allosteric binding pocket and axially dislocates helix H1 toward and helix H2 away 
from the center of the tetramer.  The dislocation of helices H1 and H2 distorts the PEP 
activation site, disrupting interactions which stabilize the R-state and creating in their place, a 
different set of subunit interactions across the C1-C4 interface.  Most prominently in the 
AMP/Glc-6-P-bound structure, Arg80, which interacts with PEP in the R-state, interacts with 
Glu6 from a symmetry related subunit in the AMP-bound state.  Arg80 and Glu6 are conserved 
in organisms possessing the signature residues of the anion activation site and the Glc-6-P 
site.  Similarities between Glc-6-P and Fru-2,6-P2 inhibition suggest an evolutionary linkage: 
both inhibitors are one-reaction products of Fru-6-P and both inhibit their respective FBPases 
synergistically with AMP. 
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Experimental: Materials and Methods 
Materials— Fru-1,6-P2, Glc-6-P, Fru-6-P, AMP, NADP+ , and ammonium molybdate 
were obtained from Sigma.  PEP came from MP biomedicals.  Zinc acetate, ascorbic acid, 
and sulfuric acid were purchased from Fisher.  1,5-anhydro-D-glucitol 6-phosphate (AnG6P) 
was synthesized from 1,5-anhydro-D-glucitol (Toronto Research Chemicals) as previously 
described (25) and quantitated using a method for phosphate detection (26).  Glucose-6-
phosphate dehydrogenase, phosphoglucose isomerase, and alkaline phosphatase were from 
Roche Applied Sciences.  All other chemicals were of reagent grade or equivalent. 
Enzyme Isolation and Purity— Native and selenomethionine-substituted proteins are 
structurally and kinetically indistinguishable and were prepared as previously described (7).  
Separate preparations were used for structure determination (SeMet) and kinetic experiments 
(native).  Isolated enzymes migrate as a single band on SDS-polyacrylamide gel 
electrophoresis representing >95% purity, have specific activities of 35-40 U/mg, and have a 
single residue type (methionine or selenenomethionine) at the N-terminus. 
Kinetic Experiments— Continuous assays for E. coli FBPase activity utilize the 
coupling enzymes phosphoglucose isomerase and glucose-6-phosphate dehydrogenase and 
monitor the formation of NADPH by either fluorescence emission at 470 nm or absorbance 
at 340 nm (13).  Assays (total volume, 2 mL) were performed at 22° C in 50 mM Hepes, pH 
7.5, with 100 µM EDTA and 150 µM NADP+ with up to saturating levels of Fru-1,6-P2 (40 
µM) and MgCl2 (10 mM).  Assays were initiated either by the addition of 1.4 µg enzyme 
(enzyme-initiated assays) or by incubating the enzyme in assay mixtures for 1 hr. at 22° C 
without MgCl2, and subsequently initiating the reaction by the addition of metal (enzyme-
incubation assays). 
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Glc-6-P is an intermediate in the coupled assay, and hence studies of Glc-6-P 
inhibition monitor FBPase turnover by the evolution of inorganic phosphate (Pi) (26).  
Reducing reagent was prepared fresh daily (26) with the addition of H2SO4 to a final 
concentration of 1 N (4).  Assays (50 mM Hepes, pH 7.5, 0.1 mM EDTA, 0.5 mM Fru-1,6-
P2, 0.75 µg enzyme, supplemented with varying amounts of PEP, AMP and Glc-6-P, total 
volume 60 µL) were incubated in 96-well microtiter plates (Evergreen) at 25o C for 1 hr. 
prior to the initiation of the reaction by the addition of 5 mM MgCl2.  The addition of 250 µL 
of reducing reagent at fixed intervals quenched the reactions.  Plates were sealed and 
incubated at 25o C for at least 2 hrs. to allow color development.  Absorbances at 655 nm 
were measured on a BioRad Benchmark microplate reader.  Standard curves used to convert 
blank-corrected A655 to [Pi] utilized NaH2PO4 and KH2PO4 (0-1.5 mM), and were linear with 
best-fit lines generated by EXCEL having R2 > 0.998.  The determination of the kinetic 
mechanism with respect to Fru-1,6-P2 and Mg2+ required lower concentrations of substrate 
than are detectable in the phosphate release assay and hence utilized the Glc-6-P analog 1,5-
anhydro-D-glucitol 6-phosphate (AnG6P) and the coupled assay system.  AnG6P at the 
highest concentration employed does not significantly lessen the flux capacity of the coupled 
assay (25). 
Initial rate data taken at saturating substrate, fixed effector and systematically varied 
inhibitor concentration were fit to a Hill equation: 
 V = V∞ + (Vmax–V∞)/[(I/I0.5)n + 1])                          EQUATION 1 
where I is the inhibitor concentration; V, Vmax and V∞ are the velocity, maximum velocity (at 
I=0), and the limiting velocity (at I saturating); n is the Hill coefficient associated with the 
inhibitor; and I0.5 is the inhibitor concentration at 50% inhibition.  Data taken from 
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experiments in which inhibitor and substrate or inhibitor and metal concentrations were 
varied systematically were fit to rapid equilibrium models for competitive, uncompetitive and 
noncompetitive inhibition, fixing the Hill coefficient of the ligand as circumstances dictate 
(n=1 or n=2).  AMP behaves cooperatively (n=2) in enzyme initiated assays or in the 
presence of PEP and non-cooperatively (n=1) in enzyme incubated assays in the absence of 
PEP, as previously described (8).  Models were fit to kinetic data using the programs 
IGORPRO (WaveMetrics) or DYNAFIT (27).  Estimates of in vivo concentrations of 
metabolite concentrations in E. coli were determined as previously described (8). 
Crystallization of AMP•Glc-6-P complex— Crystals were grown by hanging drop in 
vapor diffusion VDX-plates (Hampton Research).  Sucrose and PEG solutions were 
supplemented with 0.05% (w/v) NaN3 to reduce microbial growth.  All other solutions were 
sterile-filtered prior to use.  AMP/Glc-6-P-bound crystals grew from droplets containing 2 µL 
of a protein solution (15 mg/mL enzyme, 20 mM dithiothreitol (DTT), 0.1 mM EDTA, 5 mM 
Fru-1,6-P2, 5 mM MgCl2, and 5 mM AMP) and 2 µL of a precipitant solution (50 mM 2-(N-
Morpholino)ethanesulfonic acid-NaOH (MES-NaOH), pH 6.5, 13% (w/v) PEG 10,000, and 
20% (w/v) sucrose) and were equilibrated over 500 µL of precipitant solution.  All 
components of the protein solution were combined, except AMP, and incubated at room 
temperature for 30 min. (allowing for enzyme catalyzed equilibration of Fru-1,6-P2, Fru-6-P 
and Glc-6-P) prior to the addition of AMP.  (FBPase isolated as described here has 
endogenous phosphoglucose isomerase activity that produces Glc-6-P from Fru-6-P.  
Purifying a C-terminal polyhistidyl-tagged FBPase on a Ni-nitrilotriacetic acid (NTA) 
agarose (Novagen) removes the trace purity, but the tagged FBPase construct has 
undetermined crystallization and functional properties2).  Rod-like crystals (0.2x0.2x0.8 mm) 
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grew within 3 days at 22° C.  Crystals were cryo-protected by immersion for 60 sec. in a 
solution of 18% (w/v) PEG 20,000, 20% (v/v) 2-methyl-2,4-pentanediol, and 50 mM MES-
NaOH, pH 6.5 supplemented with dithiothreitol (DTT), ethylenediaminetetraacetic acid 
(EDTA), and ligands immediately prior to freezing in a cold stream of nitrogen. 
Data Collection— Crystals were screened at Iowa State University on a Rigaku R-
AXIS IV++ rotating anode/image plate system using CuKα radiation from an Osmic confocal 
optics system at a temperature of 110 K.  Data were collected from a single crystal at 100 K 
on Beamline 4.2.2 of the Advanced Light Source, Lawrence Berkeley Laboratory.  The 
program d*trek (28) was used to index, integrate, scale and merge intensities, which were 
then converted to structure factors using the CCP4 (29) program TRUNCATE (30). 
Structure Determination and Refinement— The program AMORE (31) using a single 
subunit from the high resolution sulfate-bound E. coli FBPase structure (PDB accession 
identifier 2GQ1) was used to construct the C1-C4 dimer of the asymmetric unit.  Manual 
adjustments in the conformation of specific residues employed the program XTALVIEW 
(32).  The resulting model underwent simulated annealing from 3000 to 300 K in steps of 25 
K, followed by 100 cycles of energy minimization and thermal parameter refinement using 
CNS (33).  Force constants and parameters of stereochemistry were from Engh and Huber 
(34).  Restraints for thermal parameter refinement were as follows: 1.5 Å2 for bonded main-
chain atoms, 2.0 Å2 for angle main-chain atoms and angle side-chain atoms, and 2.5 Å2 for 
angle side-chain atoms.  Ligands (Fru-1,6-P2, Glc-6-P, AMP, Mg2+, HPO42–, Cl–) and water 
molecules were fit to omit electron density until no improvement in Rfree was evident.  Water 
molecules with thermal parameters above 60 Å2 or more than 3.2 Å from the nearest 
hydrogen bonding partner were removed from the final model. 
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Structure and Sequence Comparisons of FBPases— Tetramer models of E. coli 
FBPase were constructed from monomer or dimer models and used in pair-wise least-squares 
superpositions between E. coli and porcine liver enzymes using the CCP4 programs 
PDBSET (35) and LSQKAB (36).  Individual displacements between Cα positions in 
structures were measured using XTALVIEW (32).  The canonical R- and T-states of porcine 
FBPase used in superpositions have PDB identifiers 1CNQ and 1EYK, respectively, whereas 
the IT- and IR-states have identifiers 1Q9D and 1YYZ.  The measured angle of rotation 
between subunit pairs in various quaternary states of FBPases is sensitive to the set of 
residues used in the least-squares fit.  Hence, previously established residues employed in the 
comparison of E. coli and porcine FBPases were used for alignments (7).  Multiple sequence 
alignments of Type I FBPases employed the program CLUSTALW (37). 
 
Results 
Inhibition of E. coli FBPase by Glc-6-P and AMP— AMP is a non-competitive 
inhibitor of E. coli FBPase with respect to the substrate Fru-1,6-P2 under all methods of assay 
and in the presence or absence of PEP.  Ki values range from 2–100 µM, being sensitive to 
the conditions of the assay and the PEP concentration.  At saturating concentrations of Fru-
1,6-P2 (40 µM) and in the presence of 1 mM PEP, AMP inhibition is mixed with respect to 
Mg2+.  The constant of dissociation for AMP from the enzyme•Fru-1,6-P2 complex (Ki=13±3 
µM) is 7-fold less than that for the dissociation of AMP from the enzyme•Fru-1,6-P2•Mg2+ 
complex (Kis=94±10 µM).  (AMP is a competitive inhibitor with respect to Mg2+ for porcine 
FBPase (38)).  Kinetic mechanisms of Glc-6-P inhibition employed the coupled assay and the 
analog AnG6P (which inhibits with 5–10-fold lower affinity than Glc-6-P).  In assays with 
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Fru-1,6-P2 or Mg2+ at saturating concentrations and 1 mM PEP, E. coli FBPase AnG6P 
inhibited non-competitively with respect to both Fru-1,6-P2 (Ki=Kis=660±70 µM) and Mg2+ 
(Ki=Kis=850±70 µM).  Glc-6-P inhibition, as measured by assays of inorganic phosphate, 
varied with fixed concentrations of PEP and AMP (FIGURE ONE and TABLE ONE).  PEP 
antagonizes AMP and Glc-6-P inhibition.  I0.5 values for Glc-6-P and AMP inhibition 
increase 10- and 4-fold, respectively over a range of 0–1 mM PEP.  500 µM Glc-6-P 
enhances AMP inhibition by up to 10-fold. 
Structure of AMP/Glc-6-P-bound E. coli FBPas)— Data and statistics for the 
structure appear in TABLE TWO.  Crystals belong to the space group P4122 (a=b=124.6, 
c=132.3 Å) with a C1-C4 dimer pair in the asymmetric unit. (See FIGURE TWO for definition 
of subunits).  Additional subunits related by crystallographic symmetry complete the 
tetrameric biological assembly.  Four AMP and two Glc-6-P molecules bind in full 
occupancy to the tetramer.  AMP molecules are at allosteric sites corresponding to those of 
the porcine tetramer (10), whereas Glc-6-P molecules bind at allosteric sites which 
incorporate a two-fold molecular/crystallographic symmetry axis.  Hence, Glc-6-P in the 
model adopts mutually exclusive modes of binding related by twofold symmetry (FIGURE 
TWO).  The allosteric sites associated with PEP activation in the R-state (8) differ in 
conformation, being occupied by chloride ions (a total of six per tetramer) and water 
molecules.  The substrate Fru-1,6-P2 and two Mg2+ are in each active site; however the 
density for the 1-phosphoryl group and the two Mg2+ associated with it is less robust than the 
density for the rest of the ligand.  A mixture of Fru-1,6-P2 and Fru-6-P probably binds to the 
active site, so while our model contains only Fru-1,6-P2 with two Mg2+, the occupancy 
factors for the 1-phosphoryl groups and the Mg2+ are set to 0.5.  Mg2+ ions occupy sites  
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FIGURE ONE.  Linear progress curves in assays of inorganic phosphate.  Assay methods appear in 
the EXPERIMENTAL section.  (A) The formation of inorganic phosphate from Fru-1,6-P2 can be 
measured after color development by absorbance at 655 nM.  Progress curves are linear for several 
minutes under all conditions.  Glc-6-P concentrations are 0 (●), 10 (∆), 25 (■), 50 (○), 100 (▲), 250 
(□), and 500 µM ( ).  (B) Glc-6-P inhibition curves at PEP concentrations of 0 (●), 50 (▲), and 1000 
µM (■).  (C) In the presence of 50 µM PEP, 500 µM Glc-6-P (○) enhances AMP inhibition relative to 
the 0 µMGlc-6-P (●).  (D) In the presence of 1 mM PEP, 500 µM Glc-6-P (○) enhances AMP 
inhibition relative to the 0 µMGlc-6-P (●) 
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TABLE ONE.  I0.5 values for the inhibition of E. coli FBPase by AMP and Glc-6-P.  Km for Fruc-
1,6-P2, Ka for Mg2+, and kcat were reported previously (I8).  Equations used in determining I0.5 values 
are in the RESULTS section, while assay conditions are in the EXPERIMENTAL section.  
Concentrations of 50 and 1000 µM PEP were chosen to approximate the low and high concentrations 
observed in vivo in E. coli (I8). 
 
 
I0.5 AMP 
(µM) 
I0.5 AMP 
(µM)  
I0.5 Glc-6-P 
(µM) 
 [PEP], µM  w/ 500 µM Glc-6-P   
0 8 ± 2 6 ± 1  38 ± 6 
50 12 ± 2 4 ± 1  100 ± 20 
1000 31 ± 7 3 ± 2  340 ± 40 
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TABLE TWO.  Statistics of data collection and refinement of the AMP•Glc-6-P complex of E. coli 
FBPase.  Space group and unit cell parameters are in the RESULTS section.  Parenthetical values 
pertain to the data shell of highest resolution shell. 
 
 Glc-6-P•AMP E. coli FBPase 
Resolution (Å) 37.8-2.05 (2.18-2.05) 
Total reflections/unique 
reflections 154,407/63,536 
Average redundancy 2.4 (2.5) 
% Completeness 96.5 (95.9) 
Rmergea 0.068 (0.255) 
I/σ(I) 9.2 (3.5) 
Number of atoms 5305 
Number of solvent sites 312 
Rfactorb 20.9 
Rfreec 23.5 
Mean thermal parameters (Å2): 
Protein 28.8 
Fru-1,6-P2 23.4 
Mg2+ 29.5 
AMP 25.0 
Glc-6-P 26.8 
Cl- 56.5 
Root mean-squared deviations: 
   Bond lengths (Å) 0.006 
   Bond angles 1.2 
   Dihedral angles 22.8 
   Improper angles 0.7 
 
TABLE TWO.  Footnotes. 
aRmerge = ΣjΣi | Iij  – <Ij> | /ΣiΣjIij, where i runs over multiple observations of the same intensity and j 
runs over all the crystallographically unique intensities. 
bRfactor = Σ || Fobs | – | Fcalc || /Σ | Fobs |, where | Fobs | > 0 
cRfree is the Rfactor based upon 10% of the data randomly culled and not used in the refinement. 
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FIGURE TWO.  Overview of the AMP•Glc-6-P complex of E. coli FBPase.  Four subunits of the 
tetramer, labeled C1–C4 by convention, bind Fru-1,6-P2 and two Mg2+ ions at the active site.  AMP 
binds at an allosteric site corresponding to the AMP binding site of porcine FBPase, displacing Phe15 
from the AMP pocket.  Helices H1 and H2 (dark lines and shading) contribute residues to the anion 
activator sites that lie between top and bottom halves of the tetramer.  Chloride ions probably occupy 
the sites in the present structure.  Glc-6-P binds at a novel site allosteric inhibitor site at the C1-C2 
subunit interface.  Electron density from Fo-Fc omit maps contoured at 3σ, using a cutoff radius of 2.0 
Å cover ligands.  This drawing was prepared with MOLSCRIPT (F1). 
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analogous to metal sites-1 and -2 of porcine FBPase (39) and have five and six coordinating 
oxygen atoms, respectively.  A complete list of protein ligand interactions appears in TABLE 
THREE.  The model does not include residues 46–67, comprising most of the dynamic loop 
and the N-terminal end of helix H3, due to the absence of interpretable electron density; 
however, residues 42–46 on the N-terminal end of the loop occupy a position consistent with 
the disengaged conformation of the dynamic loop in T-state models of porcine FBPase (40). 
The angle of rotation of subunit pair C1-C2 relative to C3-C4 about the molecular 
twofold axis that relates subunits C1 and C2 is 9°.  (By convention the R-state of porcine 
FBPase defines a subunit-pair rotation angle of 0°.  The E. coli R-state also has an angle of 
0°).  The subunit-pair rotation of the AMP•Glc-6-P tetramer is near the IT-state of the porcine 
enzyme (12–13°), observed in mutant and wild-type inhibited structures (14, 41).  In addition 
to the C1-C2 subunit-pair rotation, the subunit pair C1-C4 rotates relative to subunit pair C2-
C3 about the molecular twofold axis that relates subunits C1 and C4 (FIGURE THREE).  The 
rotation is modest (3°), but causes a significant shear between the FBP domains (residues 
200–337) of the C1 and C2 domains.  Finally, each individual subunit undergoes a rotation of 
3° about an axis that passes through the center of mass of the subunit and is perpendicular to 
the plane defined by the molecular symmetry axes that relate subunits C1 to C2 and C1 to 
C4.  The latter two rigid-body motions directly impact the integrity of the active sites, as 
presented in the next section. 
Glc-6-P Inhibition: Site of Binding and Mechanism— Glc-6-P binds as the β-anomer 
to E. coli FBPase at an allosteric site never before observed in an FBPase structure.  The 
binding site lies on a crystallographic twofold axis which relates subunits C1 and C2.  Glc-6-
P, which does not have twofold molecular symmetry, binds then with equal weight in two  
 91 
   
 
TABLE THREE.  Selected donor-acceptor interactions of bound ligands.  Residues from a 
symmetry-related subunit are marked with an asterisk.  If a ligand-protein interaction is mediated by 
water, the coordinating residue is given in parentheses. 
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FIGURE THREE.  Approximate rigid body motions induced by AMP and Glc-6-P.  (A) The 
tetramer icon and arrow indicates the region and viewing direction relative to FIGURE TWO.  Rotations 
about three axes approximate subunit motions as shown.  The rotation about the Z-axis (9o) is similar 
to that observed for the porcine FBPase in response to Fru-2,6-P2 (13o) or AMP (15o).  (B) Rotations 
which alter the association of subunit C1 and C2 may be due to the binding of Glc-6-P.  C1-C1 
monomer alignments (upper figure) of the R-state (light lines) and AMP•Glc-6-P structure (dark 
lines) reveal motion in C2 relative to C1.  C1-C2 dimer alignments (lower figure) reveal movement in 
response to Glc-6-P binding: Gln225 and Lys222 move apart from their symmetry partners in the 
opposing subunit. 
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mutually exclusive orientations related by the two-fold symmetry of the binding site.  The 
asymmetric Glc-6-P molecule binds effectively to the symmetric pocket due in part to the 
chair conformation of the pyranose ring and the equatorial positions of four hydroxyl-groups.  
Rotation of the molecule by 180o about the symmetry axis superimposes all four hydroxyl-
groups and atoms of pyranose ring onto nearly equivalent atom types and positions.  Omit 
electron density clearly defines the chirality of each of four hydroxyl-bearing carbons of the 
pyranose ring.  Glc-6-P bound in either orientation mediates interactions across the C1-C2 
interface by binding Gln225 and Lys222 and stacking both faces of the pyranose ring with 
Tyr210 (FIGURE FOUR).  The hydroxyl group of Tyr210 hydrogen bonds with two water 
molecules that in turn hydrogen bond with the 1-hydroxyl- and 6-phosphoryl-groups of Glc-
6-P.  In the twofold related orientation, Tyr210 and its two water molecules interact with the 
4-hydroxyl- and 6-phosphoryl-groups of Glc-6-P (TABLE THREE). 
In the absence of structures with only one bound ligand, we cannot ascribe 
conformational changes with certainty to any specific ligand; however, Glc-6-P seems 
responsible for the shear caused by the rotation of subunit pair C1-C4 relative to subunit pair 
C2-C3.  At the C1-C2 subunit interface of the FBP domains, where the shear is large, 
symmetry equivalent residues exhibit displacements of approximately 1 Å.  For instance, 
distances between symmetry-related Cα atoms of Gln225 and Lys222 increase by 1.5 and 0.8 Å 
relative to the R-state complex, expanding the allosteric pocket to allow for Glc-6-P ligation 
(FIGURES THREE & FOUR).  As the active site of FBPase combines residues from subunits C1 
and C2, the shear perturbs active sites. 
AMP Inhibition: Site of Binding and Mechanism— AMP binds to E. coli FBPase at 
an allosteric site corresponding to that of the porcine enzyme (10) (FIGURES TWO & FIVE).   
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FIGURE FOUR.  Glc-6-P binding site of E. coli FBPase.  The tetramer icon illustrates the viewing 
direction and region.  Glc-6-P interacts with protein atoms across the C1-C2 interface.  Shown only 
are direct polar interactions (<3.2 Å) between protein and ligand.  AnG6P (which exhibits weaker 
inhibition than Glc-6-P) does not have a 1-hydroxyl group.  The 1-hydroxyl group of Glc-6-P 
interacts with Gln225.  This drawing was prepared with XTALVIEW (32). 
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A. 
 
B. 
 
FIGURE FIVE.  Stereoview of the AMP binding site of E. coli FBPase.  (A) AMP and protein are 
covered by 2Fo-Fc electron density contoured at 1σ, using a cutoff radius of 2 Å.  (B) AMP and four 
residues depicted as van der Waals radii surfaces from XTALVIEW (32).  Atoms of Lys11, Gln12 and 
Phe15 define a surface that stacks against the adenine base.  Leu22 packs against the opposite face of 
the base.  This drawing was prepared with XTALVIEW (32). 
 
 
 96 
   
 
The backbone carbonyl of Ile8 and the side-chain of Thr23 hydrogen bond with the 6-amino 
group of the adenine base, and Tyr169 and Thr171 hydrogen bond with the adenine base 
through water molecules (TABLE THREE).  Residues 19–23, which are part of the loop 
connecting helices H1 and H2 along with Lys104 and Tyr105, interact with the 5′-phosphoryl-
group.  Lys11, Glu12, Phe15, Ile18, Leu22, Leu26, Val154, and Thr171 are in contact with the 
adenine base and/or ribose sugar.  Backbone atoms and aliphatic side-chain atoms of Lys11, 
Glu12 and Leu22 sandwich the adenine base in stacking interactions (FIGURE FIVE). 
Conformational changes in the immediate neighborhood of AMP include a 3 Å 
movement of helix H2 relative to helix H1 (FIGURE SIX).  Helix H2, slightly bent in the R-
state possibly due to PEP ligation, becomes linear in the AMP•Glc-6-P complex.  The 
movement of helix H2 and the rotation of subunit pair C1-C2 relative to C3-C4 reduce the 
volume of symmetry-paired PEP sites at the C1-C4 interface.  The distance between Cα 
atoms of Thr3 in subunits C1 and C4 (18.5 Å in the R-state, 16 Å in the AMP•Glc-6-P 
complex) provides a rough measure of the distance between symmetry-paired activation 
sites.  In the R-state, each activation site divides into binding loci for the phosphoryl and 
carbonyl groups of PEP, a total of four loci for the symmetry-paired sites.  In the AMP•Glc-
6-P complex, only three loci remain; the two binding loci for the carbonyl groups of PEP 
merge into a single locus.  Omit electron density maps reveal three spheroids of density, one 
in each of the remaining loci.  Attempts to model water molecules, metals ions, cyro-
protectants or MES did not account for the electron density and/or provide plausible 
interactions with the protein.  Chloride ions, present in crystallization experiments at a 
concentration of approximately 5 mM, provided the best fit to the electron density, a 
reasonable balance of formal electrostatic charge, and appropriate donor-acceptor distances  
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FIGURE SIX.  Orthogonal views of the Phe15/AMP pocket.  Tetramer icons and arrows indicate 
region and viewing direction of the R-state PEP-complex (left) and AMP•Glc-6-P complex (right).  
(A) The heavy and light line segments mark the relative positions of helices H1 and H2, whereas the 
open circle marks the position of PEP.  PEP binds to helices H1 and H2 allowing Phe15 to occupy the 
AMP pocket.    AMP ligation displaces Phe15 , shearing helices H1 and H2 by 3 Å, and disordering 
the PEP binding site.  (B) Orthogonal view of panel A.  This drawing was prepared with 
MOLSCRIPT (45). 
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in hydrogen bonding interactions.  Additionally, a large number of ordered water molecules 
fill the remaining space of the smaller PEP pockets.  Given the propensity for dimensional 
change and the localization of positively charged residues, several different small anions, or 
an undetermined physiological effector, may bind at this interface. 
Arg80 undergoes a significant change in conformation, linked directly to perturbations 
at the PEP pocket.  Arg80, which in the R-state interacts with PEP, moves out of the PEP 
pocket into an inter-subunit salt-link with Glu6.  The new interactions of Arg80 may be less 
effective in stabilizing the position of helix H3 than its former interactions in the R-state.  
Destabilization of helix H3 could perturb residues 46–67 at the N-terminal side of helix H3.  
If residues 46–67 are a dynamic loop involved in the binding of essential metal cofactors, 
then disorder in helix H3 probably impairs catalysis by destabilizing the active conformation 
of that loop. 
A second mechanism of inhibition evolving from disorder in helix H3 leads to Glu89 
and its chelation of metal cofactors at metal site 2.  Cα traces of the two polypeptide chains in 
the asymmetric unit of the crystal are everywhere identical (within experimental uncertainty) 
except for residues 89–100.  In chain A, Glu98–Gly99 participate in lattice contacts, and 
residues 97–100 form a Type II reverse turn similar in conformation to that of the R-state 
subunit.  In the absence of lattice contacts in chain B, residues 97–100 adopt an extended 
conformation.  Conformational changes in residues 89 and 90 compensate for those of 97–
100, limiting differences in Cα positions to residues 89–100.  Despite differences in the Cα 
positions of Glu89 in each subunit, the side-chains remain coordinated to Mg2+ (TABLE 
THREE).  Nonetheless, destabilization of helix H3 by AMP-displacement of PEP could 
perturb turn 97–100, Glu89 and the binding of Mg2+ at site 2. 
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Conservation of residues involved in allosteric regulation of E. coli FBPase—
Sequence alignments of Type I FBPases from more than 250 organisms demonstrate the 
probable conservation of the Glc-6-P binding site in organisms that have an anion activation 
site (8).  Like the anion activation site, the Glc-6-P binding site is absent in eukaryotes, the 
only exception being the eukaryotic organism Toxoplasma gondii, which has only an 
activation site.  Three signature residues (Tyr210, Lys222, and Gln225) infer Glc-6-P binding, 
and with the exception of a single lysine to arginine substitution, these three residues are 
invariant among heterotrophic organisms (TABLE FOUR)  Residues of the Glc-6-P pocket are 
conserved largely due to the lack of suitable alternatives.  For example, a phenylalanine 
replacement for Tyr210 eliminates significant hydrogen bonds involving the aromatic 
hydroxyl group.  A glutamate substitution for Gln225 introduces unbalanced charge, and non-
isosteric replacements will disrupt hydrogen bonds.  Lys222 could be replaced by arginine 
(and this may be the case in Flavobacterium sp. MED217), but the occurrence of this 
replacement in nature is rare.  The Glc-6-P pocket seems to be an all-or-nothing proposition; 
no organism identified to date has the Glc-6-P site without the anion activation site. 
Other sequence conserved residues are in involved in conformational change 
associated with effector interactions.  Phe15 occupies the AMP site when the enzyme is in the 
R-state and then packs over the bound AMP molecule (as a cover) in the inhibited state.  
Conformational changes in Phe15 and AMP ligation arguably are linked phenomena.  Gly20 is 
conserved in most eukaryotes, and some prokaryotes.  It may be a hinge that allows the 
connecting element between helices H1 and H2 to undergo conformational change in 
response to AMP ligation.  The phi/psi angles of Gly20 change from a helical conformation 
(Φ= –55°, Ψ= –40°) in the R-state to an extended conformation (Φ= 105°, Ψ= -1°) in the  
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TABLE FOUR.  Consensus residue types indicative of Glc-6-P inhibition in bacterial FBPases.  
Type-I FBPase sequence alignments from more than 250 species of eukaryotes and bacteria infer 
organisms with FBPases that bind Glc-6-P and/or PEP.  Species with key residues of the activator site 
(a total of 44) also have critical residues of the Glc-6-P site, with the exception of Toxoplasma gondii 
which does not possess the Glc-6-P binding site.  The 43 species of bacteria (identified in Ref. I8) are 
obligate heterotrophic bacteria, many of which are pathogenic.  Conserved residues Glu6, Phe15, and 
Gly20 play significant roles in mechanisms of allosteric regulation of E. coli FBPase. 
 
 
Sequence  
position in  
E.coli 
 FBPase 
Consensus 
residue 
type 
 
Exceptions 
 
Glc-6-P inhibition site 
210 Tyr none 
222 Lys Flavobacterium sp. MED217 (Arg) 
225 Gln none 
Anion (PEP/Citrate) activation Site 
5 Gly Haemophilus influenzae (Ser)  Mannheimia succiniciproducens (Asp) 
30 Lys/Arg none 
80 Arg none 
186 Val/Thr/Ser Actinobacillus pleuropneumoniae (Leu) Reinekea sp. MED297 (Ile) 
PEP/AMP Allosteric Mechanism 
6 Glu Pasteurella multocida (Gln)  Haemophilus somnus (Gln) 
15 Phe/Tyr none 
20 Gly none 
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T-like state.  Hence, the residue goes through a disallowed region of the Ramachandran plot 
as it passes between conformational states.  The reason for sequence conservation of Glu6 
with key residues of the PEP site is now clear from the AMP•Glc-6-P complex.  In the R-
state, Glu6 hydrogen bonds with solvent and with the backbone amide of Thr3, whereas in the 
AMP•Glc-6-P complex, the Arg80 interacts directly with Glu6 from a symmetry related 
subunit (C1-C4 interaction) (FIGURE SEVEN).  Neither Arg80 nor Glu6 are present in FBPases 
from organisms that have Fru-2,6-P2. 
 
Discussion 
The interactions and sequence conservation of Glu6 and Arg80 support a tetrameric 
structure for the inhibited state of E. coli FBPase.  Hydrogen bonds between Arg80 and PEP 
(R-state) and Arg80 and Glu6 (AMP•Glc-6-P complex) are analogous to C1-C4 subunit 
interactions that are broken and reformed when the porcine FBPase goes from its R- to T-
state (10, 13, 41).  A subunit dimer of E. coli FBPase is an alternative model for the inhibited 
state, but evidence exists for a dimer only in the absence of PEP and anionic ligands.  The 
dimer could exist transiently in vivo during the transition between active and inhibited states 
of the tetramer, but at present we have no evidence for a dimer as a major form of FBPase 
under physiological conditions.  Moreover, the “chloride” binding sites of the AMP•Glc-6-P 
complex could recognize a ligand of physiological significance that confers stability to an 
inhibited tetramer.  The AMP•Glc-6-P tetramer observed here may indeed be the T-state of 
the E. coli FBPase, but the C1-C2 subunit-pair rotation angle falls 6° short of that for the T-
state of porcine FBPase.  We cannot exclude the possibility of yet another ligand, binding  
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FIGURE SEVEN.  Interactions of Arg80 in the R-state PEP complex and the AMP/Glc-6-P 
complex.  The tetramer icon provides the viewing direction and region.  Electron density is from a 
2Fo-Fc map contoured at 1σ and using a cutoff radius of 2 Å.  Helices H1, H2 and H3 are in bold lines 
with dark shading.  Arg80 interacts from subunit C4 interacts with subunit C1 through an intermediary 
molecule of PEP (left).  Arg80 from subunit C4 interacts directly wit Glu6 of subunit C1 (right). Parts 
of this drawing were prepared with MOLSCRIPT (45) and XTALVIEW (32). 
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(perhaps to the chloride sites) along with AMP and Glc-6-P and causing additional subunit 
movements. 
An unambiguous determination of the individual effects of Glc-6-P and AMP on the 
structure of E. coli FBPase requires structures with only a single ligand.  Unfortunately, the 
enzyme has yet to crystallize in the presence of Glc-6-P or AMP alone.  Lack of success here 
may be due in part to the synergy of Glc-6-P and AMP inhibition.  E. coli FBPase with only 
one bound ligand may not be stable as a tetramer, or may exist as a tetramer in a manifold of 
quaternary states.  If we associate conformational change with the proximal ligand, then 
AMP would induce the C1-C2 subunit pair rotation and Glc-6-P the C1-C4 subunit pair 
rotation.  Synergism in AMP and Glc-6-P inhibition may be due to the rotations of monomers 
(FIGURE THREE) which perturb both the C1-C2 and C1-C4 interfaces of the tetramer.  
Monomer rotations, caused independently by AMP and Glc-6-P, would result in 
thermodynamic linkage and the manifestation of binding synergism.  Allosteric inhibition 
comes about presumably by the disruption of metal cofactors through the destabilization of 
helix H3 and by the perturbation of the 6-phosphoryl pocket due to the shear at the C1-C2 
interface.  The mechanism differs from porcine FBPase, as no shear is evident between 
subunits C1 and C2 in superpositions of R- and T-state C1-C2 dimers (39). 
Glc-6-P and AMP at saturating levels do not cause complete inhibition of E. coli 
FBPase (FIGURE ONE), in contrast to the complete inhibition of porcine FBPase by AMP.  
The most obvious structural difference between the two FBPases is the absence of the 
disengaged conformation of the dynamic loop in the E. coli system.  The porcine system 
stabilizes a conformation in which the dynamic loop packs with hydrophobic residues well 
removed from the active site.  Stabilization of a disengaged loop is not evident in AMP•Glc-
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6-P complex.  Interestingly, maximal AMP inhibition of the Ile10→Asp mutant of porcine 
FBPase is ~50% (42).  The dynamic loop in Ile10→Asp porcine FBPase cannot achieve the 
disengaged conformation, and as a consequence AMP cannot cause complete inhibition (41).  
The absence of complete inhibition of the E. coli system by AMP and Glc-6-P is curious.  
The complete elimination of futile cycling requires full inhibition of FBPase under conditions 
that favor glycolysis, and if elevated concentrations of Glc-6-P alone do not accomplish this 
end, then another ligand or mechanism of inhibition may be involved. 
Kinetics and structures are consistent with the mutual exclusivity of activators (PEP 
or citrate) and inhibitors (Glc-6-P and AMP).  Noncompetitive inhibition by Glc-6-P with 
respect to Fru-1,6-P2 and Mg2+ indicates Glc-6-P should bind in the presence of saturating 
cofactors and substrate, which is clearly the case for the structure presented here.  Moreover, 
the mixed inhibition by AMP with respect to Mg2+ is consistent with metals bound to sites 1 
and 2 in the presence of substrate.  The E. coli enzyme retains metals at sites 1 and 2, 
whereas the porcine enzyme, which exhibits competitive AMP inhibition with respect to 
Mg2+, has no metal at site 2 (40).  Finally, the structural mechanism that underlies PEP/AMP 
antagonism in kinetics may be the first well characterized example of the induction of an 
intramolecular conformational change by an allosteric activator which “plugs” the binding 
pocket of an allosteric inhibitor by the insertion of a single residue.  Regardless of the 
functional state of E. coli FBPase, something (AMP or Phe15) always occupies the AMP 
pocket, unlike porcine FBPase, which has an accessible AMP pocket in its R-state. 
E. coli FBPase can exist in distinct functional states, acting as a regulatory switch in 
response to natural effectors (FIGURE EIGHT).  ADP activates, but PEP and citrate inhibit PFK 
(23, 43, 44).  PEP and citrate, on the other hand, activate FBPase (8), whereas AMP is  
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FIGURE EIGHT.  Regulation of E. coli central metabolism at the FBPase/PFK step.  Solid and 
block arrows represent single and multi enzyme catalyzed reactions of the Embden-Meyerhof-Parnas 
pathway (glycolysis/gluconeogenesis) and the TCA cycle in bacteria.  2-PGA and 3-PGA are 2- and 
3-phosphoglycerate, respectively; other abbreviations are as in the text.  Dashed arrows represent the 
actions of inhibitors (–) and activators (+).  Regulation of the major PFK, encoded by the pfkA gene is 
shown.  FBPase may sense feed-forward activators (PEP, 2-PGA, 3-PGA, citrate, isocitrate), at least 
one feedback inhibitor (Glc-6-P), and an energy metabolite inhibitor (AMP). 
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inhibitory (4, 8, 9).  Unlike AMP, the concentration of which is relatively constant in vivo, 
Glc-6-P is a dynamic inhibitor of FBPase.  Its concentration rises in concert with the 
availability of glucose, and levels of Glc-6-P that cause inhibition of E. coli FBPase match 
the range of Glc-6-P concentrations in vivo (21).  Although activation of FBPase by PEP is 
potent (8), physiological combinations of Glc-6-P and AMP override activation even at PEP 
concentrations of 1 mM (TABLE ONE).  Hence, PEP and citrate under physiological 
conditions become activators of FBPase only if Glc-6-P levels are low. 
As with the anion-activation site (8), the Glc-6-P binding site may be a possible target 
for antibiotic development.  Structural and sequence information is available clearly 
demonstrating the presence of the site in pathogenic bacteria and its absence in eukaryotic 
FBPases.  But what effects will an FBPase targeted drug have on a pathogen in its host 
environment?  This depends greatly on both the pathogen and the host.  When E. coli is 
without glycolytic substrates, FBPase becomes critical.  Whether gluconeogenesis is essential 
to an organism’s survival can depend entirely on the nutrients present.  To be effective, an 
anti-microbial agent does not necessarily need to kill an organism, but simply to retard its 
growth.  Hence fungistats, like calcium propionate and potassium sorbate, are effective food 
preservatives.  The presence of at least three distinct allosteric effector sites on E. coli 
FBPase infers an emphatic requirement for rapid and precise regulation of the FBPase/PFK 
control point of glycolysis and gluconeogenesis.  Disruption of regulation here may diminish 
the vigor of the organism. 
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Abstract 
Fructose-1,6-bisphosphatase (FBPase) operates at a control point in mammalian 
gluconeogenesis, being inhibited synergistically by fructose 2,6-bisphosphate (Fru-2,6-P2) 
and AMP.  Although past investigations clearly reveal AMP and Fru-2,6-P2 ligation of an 
allosteric site and active site, respectively, the mechanism responsible for AMP/Fru-2,6-P2 
synergy is unclear.  Demonstrated here for the first time is a global conformational change in 
porcine FBPase in response to the ligation of Fru-2,6-P2 in the absence of AMP.  The change 
in quaternary structure resembles that induced by AMP, and can account for the synergy of 
AMP and Fru-2,6-P2 inhibition.  Simply stated, if two ligands can cause a conformational 
transition by different mechanisms to a common end-state, then the binding interactions of 
these ligands are linked thermodynamically, and hence, must exhibit synergism.  The 
response of FBPase from Escherichia coli offers a test of the above explanation for synergy: 
AMP and Fru-2,6-P2 are not synergistic inhibitors of the E. coli enzyme, and, consistent with 
the absence of synergism, the complex of Fru-2,6-P2 and E. coli FBPase remains in the R-
state.  These results implicate a mechanism in which Fru-2,6-P2 binds to a single active site 
of mammalian FBPase and induces a transition to a less-active intermediate T-like (IT-) state, 
and explain numerous previous observations regarding the effects of Fru-2,6-P2 on FBPase. 
 
Introduction 
Fructose-1,6-bisphosphatase (D-fructose-1,6-bisphosphate 1-phosphohydrolase, EC 
3.1.3.11; FBPase1) catalyzes the hydrolytic cleavage of the 1-phosphate from fructose 1,6-
bisphosphate (Fru-1,6-P2) to produce fructose 6-phosphate (Fru-6-P) and inorganic phosphate 
(Pi), and is a principal regulatory enzyme in gluconeogenesis (1, 2).  FBPase and fructose-6-
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phosphate-1-kinase (PFK) define a futile cycle that consumes ATP to no clear advantage.  In 
order to avoid unnecessary loss ATP, the enzymes defining futile cycles are generally subject 
to coordinate regulation.  The mammalian FBPases have two primary physiological 
inhibitors, fructose 2,6-bisphosphate (Fru-2,6-P2), the levels of which are under hormonal 
control, and AMP, which remains at a relatively constant concentration under aerobic 
conditions (3-7).  Fru-2,6-P2 binds to the active site and inhibits catalysis competitively with 
respect to Fru-1,6-P2 (6-9), whereas AMP binds to allosteric sites separated by no less than 
28 Å from the nearest active site (10).  Despite binding to well-separated sites on the enzyme, 
Fru-2,6-P2 enhances AMP inhibition by as much as 6-10 fold (6, 7).  AMP and Fru-2,6-P2 
also synergistically activate PFK in glycolysis (11, 12), and both activation of PFK and 
inhibition of FBPase occur at concentrations near the physiological range for Fru-1,6-P2 in 
the liver (6, 7, 13-15).  
Five non-homologous FBPases may exist in living organisms, though the most 
prevalent enzyme (Type I) is the sole form of FBPase in eukaryotes and the primary form in 
many bacteria (16-20).  Both the mammalian and bacterial enzymes are homotetramers with 
subunits labeled C1-C4 by convention and exist in distinct quaternary states (R and T), the 
relative stability of which depends upon ligation by physiological effectors.  AMP ligation 
transforms the active mammalian R-state enzyme, observed in crystal structures in the 
absence of inhibitors (21-24), to an inactive T-state (10, 24-26).  Transition to the T-state 
entails a global rearrangement by a twist of 15o between upper (C1-C2) and lower (C3-C4) 
subunit pairs (10, 27).  Mutations that specifically destabilize the T-state are in intermediate 
quaternary states, IR (27) and IT (28), in the presence of AMP.  In porcine liver enzyme, the 
AMP induced transition to the T-state displaces a catalytic loop (residues 52–72) from the 
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active site, disrupting one of three binding sites for metal cofactors (23, 24, 27, 28), 
consistent with the mechanism of competitive inhibition of catalysis by AMP with respect to 
Mg2+ (29). 
Four molecules of Fru-2,6-P2 bind per tetramer (30, 31).  Fru-2,6-P2 is a linear 
competitive inhibitor with respect to Fru-1,6-P2, lowers the concentration of AMP necessary 
for 50% inhibition of FBPase (AMP/Fru-2,6-P2 synergism), and induces sigmoidicity in the 
binding of Fru-1,6-P2 (7, 32); an effect not caused by AMP (3).  Binding studies are 
consistent with kinetics: the presence of Fru-2,6-P2 enhances AMP binding (31).  Moreover, 
the binding of one equivalent of Fru-2,6-P2 elicits change in UV difference spectra similar to 
that induced by AMP, inferring a conformational change caused by Fru-2,6-P2 that is similar 
to that induced by AMP (31).  Although these findings are credible, some of the 
conformational changes in FBPase that underlie them are unclear.  We don’t know how 
FBPase responds to Fru2,6-P2 alone.  The Fru-2,6-P2/AMP complex is isomorphous to the 
AMP complex (T-state) (26) and previously determined Fru-2,6-P2 complexes in the absence 
of AMP are in the R-state; however, these R-state complexes either lack density for the 2-
phosphoryl group (a likely consequence of degradation of Fru-2,6-P2 to Fru-6-P (8)) or are 
the result of soaking R-state crystals with the inhibitor (9).  The crystallization of FBPase 
with Fru-2,6-P2 from solution and clear evidence of an intact ligand would go a long way to 
understanding the conformational changes induced by Fru-2,6-P2. 
One proposed explanation of AMP/Fru-2,6-P2 synergy has Fru-2,6-P2 bind to the 
AMP site.  The experimental basis of this hypothesis is the presence of bound Fru-2,6-P2 at 
the AMP site in soaked R-state crystals (9).  Mutations in both the active site (33), and AMP 
site (34), however, indicate potent inhibition and synergism comes from Fru-2,6-P2 ligation 
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of the active site.  Additionally, binding studies with native and acetylated proteins (30, 31), 
and kinetic studies (6, 35-37) support Fru-2,6-P2 binding only in the active site. 
Reported here for the first time are co-crystallizations of porcine FBPase with Fru-
2,6-P2 and either Mg2+ or Zn2+.  Fru-2,6-P2 ligation of the active site alone clearly causes a 
quaternary transition to the IT-state, similar to that induced by AMP.  Hence, we propose 
AMP/Fru-2,6-P2 synergism is a consequence of thermodynamic linkage: two ligands by 
separate mechanisms promote a quaternary transition to a common end-state.  The enzyme 
from Escherichia coli provides an opportunity to test the thermodynamic linkage hypothesis.  
E. coli FBPase in the presence of anionic activators (phosphoenolpyruvate (PEP) or citrate) is 
in an active R-state identical to the porcine enzyme (38).  Fru-2,6,-P2, although absent in 
prokaryotes (39-41), inhibits E. coli FBPase, but without AMP/Fru-2,6-P2 synergism (42).  
The effect of Fru-2,6-P2 on E. coli FBPase in the presence of allosteric activators (PEP or 
citrate) is unknown, as is the kinetic mechanism of Fru-2,6-P2 inhibition.  Demonstrated here 
is a competitive mechanism of inhibition by Fru-2,6-P2 with respect to Fru-1,6-P2 in the 
presence of allosteric activators.  Fru-2,6-P2 inhibition is not synergistic with AMP, and on 
the basis of the crystal structure of the ligated enzyme complex, Fru-2,6-P2 causes no global 
conformational change.  AMP, in conjunction with Glc-6-P, as reported previously (43) does 
cause a global conformational change in E. coli FBPase.  Hence, AMP and/or Fru-2,6-P2 do 
not independently cause global conformational changes to a common end state, and indeed 
lack synergism in their inhibition of E. coli FBPase, as is consistent with the hypothesis of 
thermodynamic linkage. 
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Experimental: Materials and Methods 
Materials— Fru-1,6-P2, Fru-2,6-P2, NADP+, DEAE-Sepharose and Cibacron Blue-
Sepharose came from Sigma.  Glucose-6-phosphate dehydrogenase and phosphoglucose 
isomerase were from Roche Applied Sciences.  All other chemicals were of reagent grade or 
equivalent. 
Preparation of porcine and E. coli FBPases— Porcine FBPase was isolated as 
previously described (44) with minor modifications.  Following elution from the Cibacron 
Blue-Sepharose column, the pH of the protein was adjusted from 7.5 to 8.3 prior to loading 
onto DEAE-Sepharose (equilibrated with 5 mM MgCl2, 20 mM Tris-HCl pH 7.5).  
Subsequent desalting by a Sephadex G-50 column (equilibrated with 20 mM 
KH2PO4/K2HPO4, pH 7.0) replaced dialysis.  Protein intended for crystallography was 
concentrated to 10 mg/mL in the desalting buffer and filtered through a 0.22 µM filter.  
Protein was flash frozen in 200 µL aliquots using a dry-ice/ethanol bath and stored at –80 oC.  
Protein concentrations were determined by the method of Bradford (45), using bovine serum 
albumin as a standard.  Selenomethionine-substituted E. coli FBPase was isolated as 
previously described (20). 
Crystallization of Fru-2,6-P2 complexes— Crystals were grown by hanging drop in 
vapor diffusion VDX-plates (Hampton Research).  Sucrose and PEG solutions were 
supplemented with 0.05% (w/v) NaN3 to limit microbial growth.  All other solutions were 
sterile filtered prior to use.  Crystals of the E. coli FBPase citrate•Fru-2,6-P2-complex grew 
from droplets containing 2 µL of a protein solution (15 mg/mL enzyme, 20 mM 
dithiothreitol, 0.1 mM EDTA, 5 mM Fru-1,6-P2, 5 mM Fru-2,6-P2, 5 mM MgCl2) and 2 µL 
of a precipitant solution (50 mM sodium citrate pH 5.3, 25% (w/v) PEG 1500 and 20% (w/v) 
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sucrose).  Crystals of the porcine FBPase Mg2+•Fru-2,6-P2-complex grew from droplets 
containing 2 µL of a protein solution (10 mg/mL enzyme, 0.2 mM EDTA, 5 mM Fru-2,6-P2, 
5 mM MgCl2) and 2 µL of a precipitant solution (8.5% (w/v) PEG 3350, 5% (v/v) t-butanol, 
27% (v/v) glycerol, and 10 mM Hepes-NaOH, pH 7.5).  Crystals of the porcine FBPase 
Zn2+•Fru-2,6-P2-complex grew from droplets containing 2 µL of a protein solution (10 
mg/mL enzyme,  5 mM Fru-2,6-P2, 2 mM ZnCl2) and 2 µL of a precipitant solution (10% 
(w/v) PEG 3350, 5% (v/v) t-butanol, 27% (v/v) glycerol and 100 mM Hepes-NaOH, pH 7.0).  
In all cases the droplets were equilibrated over 500 µL of precipitant solution.  Equal-
dimensional crystals (0.2–0.3 mm) grew within 3 days at 22 °C.  Crystals were frozen 
directly in a cold stream of nitrogen without additional cyroprotectants. 
Data Collection— Crystals were screened and data were collected for the bacterial 
enzyme at Iowa State University on a Rigaku R-AXIS IV++ rotating anode/image plate 
system using CuKα radiation from an Osmic confocal optics system at a temperature of 110 
K.  Data were collected from the mammalian enzyme crystals at 100 K on Beamline 4.2.2 of 
the Advanced Light Source, Lawrence Berkeley Laboratory.  The program d*trek (46) was 
used to index, integrate, scale and merge intensities, which were then converted to structure 
factors using the CCP4 (47) program TRUNCATE (48). 
Structure Determination and Refinement— Creation of initial structural models and 
the development of molecular replacement solutions utilized the CCP4 programs PDBSET 
(49) and LSQKAB (50) and the program AMORE (51).  The canonical R-state porcine 
FBPase model (PDB accession identifier 1CNQ), less ligands and water molecules, was used 
to build a model for the C1-C2 dimer, employed in molecular replacement phasing and initial 
refinement of the porcine Mg2+•Fru-2,6-P2-complex.  The final refined Mg2+•Fru-2,6-P2-
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complex was used as the initial model for the Zn2+•Fru-2,6-P2-complex.  The initial model 
for the E. coli citrate•Fru-2,6-P2-complex was the R-state (citrate-bound) E. coli FBPase 
structure (PDB accession identifier 2OWZ) from which ligands and waters had been 
removed. 
Structural models underwent energy minimization followed by individual thermal 
parameter refinement using CNS (52).  Force constants and parameters of stereochemistry 
were from Engh and Huber (53).  Restraints for thermal parameter refinement were as 
follows: 1.5 Å2 for bonded main-chain atoms, 2.0 Å2 for angle main-chain atoms and angle 
side-chain atoms, and 2.5 Å2 for angle side-chain atoms.  Non-crystallographic restraints 
were not used in the refinement.  Manual adjustments in the conformation of specific 
residues employed the program XTALVIEW (54).  Ligands (Mg2+, Zn2+, Fru-2,6-P2, HPO42-, 
citrate) and water molecules were fit to omit electron density until no improvement in Rfree 
was evident.  Water molecules with thermal parameters above 55 Å2 or more than 3.2 Å from 
the nearest hydrogen bonding partner were removed from the final model.  Protein geometry 
was analyzed using the program PROCHECK (55), which confirmed that no residues are in 
disallowed regions of the Ramachandran plot. 
Superposition of Structures— Dimer and tetramer models of FBPase were 
constructed from single subunits and used in pair-wise least-squares superpositions between 
enzymes using the CCP4 programs PDBSET (49) and LSQKAB (50).  Individual 
displacements between Cα positions in structures were measured using XTALVIEW (54).  
The canonical R- and T-states of porcine FBPase used in superpositions have PDB identifiers 
1CNQ and 1EYK, respectively, whereas the IT- and IR-states have identifiers 1Q9D and 
1YYZ, respectively.  The citrate-bound model of E. coli FBPase (PDB identifier 2OWZ) was 
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the basis for comparisons of E. coli FBPase structures.  The angle of rotation between 
subunit pairs in various quaternary states of FBPases is sensitive to the subset of residues 
used in the least-squares fit.  Previously established subsets of residues used to compare 
porcine structures (27) and E. coli and porcine structures (20) were used for alignments 
unless noted otherwise. 
Kinetic Experiments— FBPase activity assays employ the coupling enzymes 
phosphoglucose isomerase and glucose-6-phosphate dehydrogenase and monitor the 
formation of NADPH by either absorbance at 340 nm or fluorescence emission at 470 nm 
(27).  Assays (total volume, 2 mL) were conducted at 22 °C in 50 mM Hepes, pH 7.5, with 
100 µM EDTA and 150 µM NADP+.  150 mM KCl was added for porcine FBPase assays 
only.  Saturating levels of Fru-1,6-P2 (40 or 20 µM) and MgCl2 (10 or 5 mM) for E. coli and 
porcine enzymes, respectively, were used to measure specific activity.  E. coli FBPase (but 
not porcine FBPase) is sensitive to the method of assay and so two assays were employed 
(38).  Assays were either initiated by the addition of 1.4 µg enzyme (enzyme-initiated assays) 
or by incubating the enzyme in assay mixtures for 1–2 hr. at 22 °C without MgCl2, and 
subsequently initiating the reaction by the addition of metal (enzyme-incubation assays).  All 
porcine FBPase assays were initiated with the addition of metal. 
 
Results 
Enzyme Purity and Fidelity— Preparations of native and selenomethionine-
substituted E. coli FBPase, used for kinetic and structural investigations, respectively, have 
specific activities of 35-40 U/mg and appear as single bands on sodium dodecylsulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) (a protein in at least 95% purity).  N-
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terminal residue analysis reveals a single residue type (methionine or selenomethionine), 
indicating no N-terminal proteolysis.  Purified porcine FBPase used in this investigation has 
a specific activity of 30 U/mg, migrates as a single band on sodium dodecylsulfate 
polyacrylamide gel electrophoresis (SDS-PAGE), and has a pH 7.5/9.6 ratio of 3.3 indicative 
of a non-proteolyzed state. 
Kinetics of AMP and Fru-2,6-P2 inhibition— Enzymes isolated here have kinetic 
properties as previously reported for porcine (56) and E. coli (38) FBPases, and have the 
properties relating to AMP/Fru-2,6-P2 synergy that agree with previous observations (6, 7, 
42).  Enzyme initiated or metal initiated assays of E. coli FBPase result in different I0.5 values 
and Hill coefficients for AMP (38).  Regardless, Fru-2,6-P2 has no effect on AMP inhibition 
of E. coli FBPase using either assay method (FIGURE ONE).  Lines in the panels A, B, & C of 
FIGURE ONE are from a fit of data to a Hill equation: 
 V = Vmax/[(I/I0.5)n + 1]           EQUATION ONE 
where V and Vmax are the observed and maximum velocities, I is the concentration of AMP, 
I0.5 is the concentration of inhibitor that gives 50% inhibition, and n is the Hill coefficient.  
The Hill coefficient for AMP refines to (1.0±0.2) and (1.7±0.2) for data of panel A and B, 
respectively, as is consistent for the two assay methods (38).  In panel C of FIGURE ONE, 
however, the Hill coefficient declines from 1.9±0.2 to 1.3±0.1 as the concentration of Fru-
2,6-P2 increases.  Moreover, Fru-2,6-P2 clearly enhances the inhibition of porcine FBPase by 
AMP.  I0.5 values for AMP inhibition of porcine FBPase decline as a function of increasing 
Fru-2,6-P2 concentration (FIGURE ONE, panel D).  The decrease in I0.5 of AMP follows the  
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FIGURE ONE.  The effects of Fru-2,6-P2 on AMP inhibition of porcine and E. coli FBPases.  Fru-
2,6-P2 has no effect on AMP inhibition of E. coli FBPase in enzyme initiated (A) or enzyme 
incubated (B) assays.  Concentrations of Fru-2,6-P2 are 0 ( ), 1 (▲), 4 (■), and 8 (●) µM in both A 
and B.  Fru-2,6-P2 enhances AMP inhibition of porcine FBPase (C).  Fru-2,6-P2 concentrations are 0 
( ), 0.5 (▲), 1 (■), 5 (●), 10 (∆), and 25 (○) µM.  The concentration of AMP producing 50% 
inhibition of porcine FBPase (I0.5) decreases with increasing [Fru-2,6-P2] (D).  Lines are fits of the 
data to EQUATIONS ONE & TWO, defined in the results section. 
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following empirical relationship, which is of the same form as the Hill equation with n set to 
unity: 
I0.5 = I0.5min + (I0.5max – I0.5min)/([Fru-2,6-P2]/α0.5 + 1)                   EQUATION TWO 
In the above, I0.5 is the concentration of AMP causing 50% inhibition, I0.5min is the limiting 
I0.5 value for AMP inhibition in the presence of an infinite concentration of Fru-2,6-P2, I0.5max 
is the observed value for 50% inhibition by AMP in the absence of Fru-2,6-P2, and α0.5 is the 
concentration of Fru-2,6-P2 that produces 50% of the synergistic effect.  α0.5 represents an 
apparent dissociation constant for Fru-2,6-P2, and its fitted value from the data of panel D is 
0.36±0.04 µM, which is within the range of observed dissociation constants (0.1–2 µM) 
reported for Fru-2,6-P2 from kinetics and binding experiments (6, 7, 30, 32, 57).  
Enhancement of AMP inhibition by Fru-2,6-P2 is simply I0.5max/I0.5min, approximately 4-5 fold 
for the fit line for the data of FIGURE ONE.  I0.5 for Fru-2,6-P2 inhibition also decreases as a 
function of AMP concentration (7) (data not shown). 
Fru-2,6-P2-bound Structures of Porcine FBPase— Crystals of Fru-2,6-P2-bound 
porcine FBPase belong to the space group P21212 for Mg2+ (a = 59.2, b = 165.6, c = 79.6 Å) 
and Zn2+ (a = 59.0, b = 165.7, c = 79.2 Å) complexes.  Statistics of data collection and 
refinement for structures presented here are in TABLE ONE.  The two mammalian structures 
are isomorphous and contain a C1-C2 subunit pair in the asymmetric unit.  A second subunit 
pair (C3-C4) (related by crystallographic symmetry to the first) completes the biological 
homotetramer.  The models of porcine FBPase lack density for residues at the N-terminus 
and begin with Asn9, but are otherwise complete for all 337 residues.  Only residues 63–70 
are not in strong electron density.  These residues are part of the dynamic loop, which is in  
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Table ONE.  Statistics of data collection and refinement of Fru-2,6-P2 complexes of porcine and 
E. coli FBPases.  Space group and unit cell parameters are in the Results section.  Parenthetical 
values pertain to the highest resolution shell of data. 
 
 
TABLE ONE.  Footnotes. 
 
aRmerge = ΣjΣi | Iij  – <Ij> | /ΣiΣjIij, where i runs over multiple observations of the same intensity and  
j runs over all the crystallographically unique intensities. 
 
bRfactor = Σ || Fobs | – | Fcalc || /Σ | Fobs |, where | Fobs | > 0 
 
cRfree is the Rfactor based upon 10% of the data randomly culled and not used in the refinement. 
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the disengaged conformation in both the Mg2+- and Zn2+-bound complexes of the porcine 
enzyme.  Individual polypeptide chains of the dimer in the asymmetric unit have no 
significant differences in conformation.  Cα alignments using all residues of each polypeptide 
chain, save for the last six residues at the C-terminus, give root-mead-squared deviations of 
0.15 and 0.22 Å for the Mg2+ and Zn2+ complexes, respectively, values in line with estimated 
coordinate uncertainty.  The largest structural divergence, other than conformational 
differences of C-terminal residues, occurs where electron density is weak in the dynamic 
loop. 
Strong electron density covers Fru-2,6-P2 bound in the active sites of the Mg2+ and 
Zn2+ porcine complexes (FIGURE TWO).  Mg2+ is in metal site 1, coordinated by Asp118 
Asp121, Glu280, a water molecule, and the 1-hydroxyl-group of Fru-2,6-P2, and near metal site 
3, coordinated by Glu97 and five water molecules.  Two of these coordinated water molecules 
also interact with the 2-phosphoryl-group of Fru-2,6-P2.  To the best of our knowledge, this is 
the first instance of metal binding near site 3 without the dynamic loop in its engaged 
conformation; in such conformations, the metal a site 3 interacts with Glu97 and Asp68 of the 
loop.  Zn2+ is only at site 1, binding Asp118, Asp121, Glu280, one water molecule and the 1-
hydroxyl group of the inhibitor.  As others suggest AMP/Fru-2,6-P2 synergy arises from Fru-
2,6-P2 binding at the AMP site, electron density maps (2Fo-Fc) and (Fo-Fc) calculated with or 
without modeled ligands reveal only a sphere of electron density at the binding locus for the 
5′-phosphoryl group of AMP, with no interpretable density evident for additional atoms of a 
more complex ligand.  A complete list of ligand interactions for structures reported here are 
in TABLE TWO. 
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FIGURE TWO (on previous page).  Overviews of Fru-2,6-P2-bound porcine and E. coli FBPases.  
(A) Porcine Fru-2,6-P2•Mg2+ FBPase (left) has subunits labeled C1-C4 and adopts a intermediate 
quaternary conformation between the canonical R- and T- states.  The dynamic loop (residues 52-72, 
darkened lines) is in the disengaged conformation, normally observed in AMP-bound structures.  
Active site ligands and some residues are shown in stereo and are covered in difference density (2Fo-
Fc) contoured at 2σ.  A complete list of ligand-protein interactions is given in TABLE TWO. (B) 
Active site ligands of the Fru-2,6-P2•Zn2+ porcine enzyme are shown covered in omit density (Fo-Fc) 
contoured at 4σ.  (C) E. coli FBPase with bound Fru-2,6-P2, Mg2+, and citrate adopts a quaternary 
conformation identical to the canonical R-state of the mammalian enzyme, and the previously 
described R-state of the E. coli enzyme.  Fru-2,6-P2 and one Mg2+ bind in the active site while citrate 
binds to anion activation site found in some bacterial FBPases.  The dynamic loop (residues 42-63, 
darkened lines), observed for the first time in the bacterial enzyme, adopts an engaged conformation.  
Ligands are covered in omit density (Fo-Fc) contoured at 4σ.  Parts of this drawing were prepared with 
XTALVIEW (54) and MOLSCRIPT (74). 
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TABLE TWO.  Selected donor-acceptor interactions of bound active site ligands.  Homologous 
interactions in all three structures are listed horizontally in the table below.  Citrate interactions (E. 
coli structure) are identical to those previously reported in the R-state model (38).  Residues from a 
symmetry-related subunit are marked with an asterisk.  If a ligand-protein interaction is mediated by 
water, the coordinating residue is given in parentheses.  Differences in Fru-2,6-P2 ligation between 
porcine and E. coli are shown in bold typeface. 
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The Mg2+ and Zn2+-bound structures of porcine FBPase exhibit no significant 
differences beyond coordinate error with monomer alignments resulting in an overall root-
mean-squared deviation of 0.14 Å between corresponding Cα positions.  These structures 
differ then by metal interactions.  The porcine Fru-2,6-P2 complexes differ from the 
canonical R-state of FBPase by changes in quaternary structure and the conformation of the 
dynamic loop.  The rotation angle between subunit pairs C1-C2 and C3-C4 of the Fru-2,6-P2 
complexes differ by 13° from the canonical R-state and 2° from the T-state.  The quaternary 
state of the Fru-2,6-P2 bound mammalian enzymes is close to that of the IT-state (subunit pair 
rotation angle of 12°), recognized first in a enzyme complex with the synthetic inhibitor 
OC252 (44). 
Quaternary state (subunit-pair rotation), space group and state of ligation of many 
FBPase tetramers are in TABLE THREE.  In addition to the R-state, which crystallizes in two 
space groups, IT-state structures are also in two space groups (I222 and P21212).  Hence, one 
cannot easily attribute the quaternary state to “packing forces” of the crystal.  R-state 
structures vary by ~0.5o from each other, and the Mg2+ and Zn2+ Fru-2,6-P2 complexes 
reported here deviate by ~0.75o.  Moreover, the OC252-complex, AMP-bound Ile10→Asp 
FBPase, and Fru-2,6-P2 ligated structures have rotation angles of 12–13o.  Hence, the IT 
quaternary state seems as well-defined as any quaternary state of porcine FBPase.  The high 
resolution (1.5 Å) Fru-2,6-P2•Mg2+ porcine structure is also the highest resolution structure of 
a T-like inhibited state of FBPase. 
Fru-2,6-P2-bound structure of E. coli FBPase— Crystals of E. coli FBPase with 
bound Fru-2,6-P2, Mg2+, and citrate belong to the space group I222 (a = 44.0, b = 82.3, c = 
174.2 Å) and are isomorphous with citrate or PEP complexes (38).  One monomer is present  
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TABLE THREE.  Selected porcine and E. coli FBPase structures.  FBPase crystallizes in different 
quaternary states independent of space group but dependent upon the state of ligation.  Subunit-pair 
rotation angles are defined with respect to the canonical R-state.  The C3-C4 subunit pair of a 
tetramer of undetermined quaternary state is superimposed on the C3-C4 subunit pair of the canonical 
R-state.  The rotation that brings the C1-C2 subunit pair of the R-state into superposition with the C1-
C2 subunit pair of the tetramer of undetermined quaternary state is the subunit pair rotation.  The 
three structures presented here are in bold typeface. 
 
 
Quaternary 
state 
Subunit-
pair 
Rotation Ligands 
Space 
group 
Resolution 
(Å) 
PDB 
ID Ref. 
Porcine FBPase: 
R-state 0o  none P3221 2.80 2FBP (I10) 
R-state 0o Fru-6-P, Pi, Zn2+ I222 2.27 1CNQ (I13) 
R-state 0o Fru-6-P, Pi, Mg2+ I222 2.32 1EYI (I13) 
IR-statea 3o AMP, Fru-6-P, Pi, Mg2+ I222 1.85 1YYZ (I16) 
IT-state 12o OC252, Fru-6-P, Pi, Mg2+ P21212 2.35 1Q9D (E1) 
IT-stateb 12o AMP, Fru-6-P, Pi, Zn2+ I222 1.83 2F3D (I17) 
IT-state 13o Fru-2,6-P2, Pi, Mg2+ P21212 1.50 NAc – 
IT-state 13o Fru-2,6-P2, Pi, Zn2+ P21212 2.03 NAc – 
T-state 15o AMP, Fru-6-P, Pi, Mg2+ P21212 2.28 1EYJ (I13) 
T-state 15o AMP, Fru-6-P, Pi, Zn2+ P21212 2.23 1EYK (I13) 
T-state 15o Fru-2,6-P2, AMP, Zn2+ P21212 2.00 1FRP (I15) 
E. coli FBPase: 
R-state 0o Fru-6-P, PEP I222 2.18 2OX3 (I24) 
R-state 0o Fru-6-P, citrate I222 2.18 2OWZ (I24) 
R-state 0o Fru-2,6-P2, citrate, Mg2+ I222 2.18 NAc – 
I-like state 6o SO42– I222 1.45 2GQ1 (I23) 
 
TABLE THREE.  Footnotes. 
aAla54→Leu FBPase. 
bIle10→Asp FBPase 
cNA: not available. 
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in the asymmetric unit.  The tetramer (reproduced from crystallographic symmetry) is in the 
canonical R-state even though Fru-2,6-P2 is in the active site, covered by strong electron 
density (FIGURE TWO).  One Mg2+ is at metal site 1, and citrate is at the allosteric activation 
site.  The model has all 332 residues of E. coli FBPase in good or strong electron density.  
The dynamic loop (residues 42–63) appears ordered for the first time in a crystal structure of 
a bacterial Type I FBPase, adopting an engaged conformation in association with Fru-2,6-P2 
at the active site.  The engaged dynamic loop stands in contrast to the mammalian-Fru-2,6-P2 
complexes reported here that have dynamic loops in disengaged conformations.  Glu60 
(corresponding to Asp68 in pig FBPase) interacts with the 2-phosphoryl-group through water 
molecules and interacts directly with Arg271.  Additionally, Wat462 which interacts with Glu60 
and Glu89, occupies the position corresponding to metal site 3 in the mammalian enzyme.  
Modest electron density and donor acceptor distances of ~2.8 Å are not consistent with the 
assignment of Mg2+ to the electron density. 
 
Discussion 
Initial explanations for AMP/Fru-2,6-P2 synergy have Fru-2,6-P2 binding to the AMP 
site or another unknown allosteric site (9, 33, 58-62); however, Fru-2,6-P2 (and not AMP) 
protects the active site from acetylation (31).  In crystal structures, Lys274 binds directly to 
the endocyclic oxygen atom of the furanose ring of Fru-6-P and Fru-2,6-P2 (8, 9, 22), and the 
mutation of Lys274 to alanine reduces the Km for Fru-1,6-P2 and Ki for Fru-2,6-P2, with no 
effect on AMP inhibition (33).  The Lys274→Ala enzyme still exhibits AMP/Fru-2,6-P2 
synergy, albeit at an elevated concentration of Fru-2,6-P2 that correlates quantitatively with 
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the increase in Ki due to mutation.  (At concentrations of Fru-2,6-P2 below the Ki for the 
mutant enzyme, the authors claim a synergistic effect for Fru-2,6-P2 on AMP inhibition (33).  
The “effect”, however, is at the level of noise).  Mutations at the AMP site have no effect on 
Fru-2,6-P2 inhibition or synergy, save for mutations that drastically reduce (or eliminate) 
AMP inhibition (34).  Mutations that reduce AMP affinity by less than 100-fold have no 
effect on the ability of 1 µM Fru-2,6-P2 to enhance AMP inhibition by 2-3 fold (34).  
Mutations of the AMP pocket do not support a functional response for the binding of Fru-
2,6-P2 at the AMP site.  Indeed, AMP/Fru-2,6-P2 synergy is a property of all mutant forms of 
FBPase that retain some significant level of AMP and Fru-2,6-P2 inhibition. 
A second model has Fru-2,6-P2 binding at the active site, and incorporates 
observations from several investigations: AMP and Fru-2,6-P2 induce similar conformational 
changes in FBPase on the basis of UV difference spectroscopy (31) and fluorescence from a 
tryptophan reporter group (56).  Fru-2,6-P2 and Fru-1,6-P2 bind to a common site with high 
affinity to two forms of FBPase (63, 64).  In this model, AMP- and Fru-2,6-P2-ligation result 
in a state of FBPase deficient in essential metal cofactors (63). AMP/Fru-2,6-P2 synergy 
would arise from thermodynamic linkage in the displacement of metals, but the structural 
basis for that linkage was unclear until Choe et al. (23) observed the dynamic loop in its 
engaged conformation.  Displacement of the loop disrupts metal binding sites, as subsequent 
investigations in directed mutations, crystallography and kinetics confirmed (24, 56).  
Synergy arises in the model of Choe et al. (23) not only from the release of metal cofactors, 
but from the stabilization of the disengaged loop by AMP and Fru-2,6-P2.  In order to 
stabilize a disengaged dynamic loop, however, which has been observed only in T-like 
quaternary states of FBPase, one must demonstrate that Fru-2,6-P2 alone causes a transition 
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from the R- to a T-like state with a disengaged dynamic loop and an active site impaired in 
metal binding.  The present study reveals Fru-2,6-P2 bound only to the active sites, with 
dynamic loops in the disengaged conformation, active sites depleted of metal co-factors, and 
a quaternary state for the tetramer similar to that observed in the AMP-ligated form of the 
enzyme. 
By the model above, AMP/Fru-2,6-P2 synergy arises from the ability of AMP and 
Fru-2,6-P2 to individually transform FBPase from the R-state to a T-like state.  The 
mechanism by which AMP promotes the T-state is in the literature (10, 22, 27, 28, 65).  The 
binding of AMP to the R-state induces a shear between helices H1 and H2 that disrupts 
hydrogen bonds between subunit pairs C1-C2 and C3-C4.  Transition to the T-state restores 
disrupted hydrogen bonds. 
The mechanism by which Fru-2,6-P2 causes a transition to the T-state is less certain, 
because we lack an R-state ligated by Fru-2,6-P2 that reveals conformational change in the 
absence of a quaternary transition.  Nonetheless superpositions of porcine R-state FBPase 
and Fru-2,6-P2-bound FBPase reveal changes in tertiary structure.  The largest change is the 
displacement of the engaged dynamic loop to its disengaged conformer (displacements of up 
to 36 Å).  Second in magnitude is the movement (displacements up to 4 Å) of loop 264–274.  
Finally small (0.5–2.0 Å), but significant conformational changes occur in the neighborhood 
of the Fru-2,6-P2 molecule.  The immediate effect of the Fru-2,6-P2 ligation of the R-state is 
the probable exclusion of the engaged conformation of the dynamic loop.  Superposition of 
the 6-phosphoryl pocket of the R-state porcine enzyme onto corresponding residues of the 
Fru-2,6-P2 active site reveals movement in residues 97–99 and 123–126 toward each other 
and the 2-phosphoryl group of the ligand (FIGURE THREE).  These movements could result  
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FIGURE THREE.  Movements in porcine FBPase correlated with Fru-2,6-P2 ligation.  Fru-2,6-P2 
and Mg2+ are shown bound in the active site of porcine FBPase.  Selected residues from Fru-2,6-P2-
bound enzyme (heavy lines) and R-state enzyme (light lines) are shown.  Alignment of residues 
which bind the 6-phosphoryl- side of Fru-2,6-P2 (away from the 2-phosphoryl-group) illustrate the 
relative movements of residues near the 2-phosphoryl- group.  Ser123,  Ser124, and proximal residues 
move toward residues 73-75 and 97-99.  Glu97 and Glu98 and surrounding protein elements move 
toward the Fru-2,6-P2 molecule.  Correlated movements in Asp74 of Helix H3 prevent a steric clash 
with Glu98.  These movements occur in both porcine Fru-2,6-P2-bound models but do not occur in 
Fru-2,6-P2-bound E. coli FBPase.  This drawing was prepared with XTALVIEW (54). 
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from the relaxation of the active site in the absence of an engaged loop, or a conformational 
change induced by Fru-2,6-P2. The movement of residues 97–99 would place Glu98 in steric 
conflict with Asp74 of an engaged loop (FIGURE FOUR). The movement of residues 97–99 
would place Glu98 in steric conflict with Asp74 of an engaged loop.  Asp74 interacts with the 
backbone amide group of Lys71, a linkage critical to the stability of the engaged 
conformation of the dynamic loop (23, 66).  Loss of the engaged conformation probably 
destabilizes the R-state, but it is unclear whether the loss of only one engaged loop of the 
tetramer is sufficient to cause an R- to T-state transition.  Results from UV difference 
spectroscopy are based on the titration of FBPase with Fru-2,6-P2 in the absence of substrate 
and metals (31), and may not reflect the behavior of the enzyme in the presence of saturating 
substrate (or products) and metals. 
The model for Fru-2,6-P2 inhibition and AMP/Fru-2,6-P2 synergism presented here 
explains the dependence of inhibition on the type of metal cofactor.  I0.5 concentrations of 
Fru-2,6-P2 and AMP depend on the type of metal cofactor, with I0.5 values being lowest in 
the presence of Mg2+ highest in the presence of Mn2+ (32).  Moreover, the manifestation of 
AMP/Fru-2,6-P2 synergy correlates with I0.5 values of the inhibitors (32).  Fluorescence 
experiments using Trp57 as a reporter group reveal Mn2+ (followed by Zn2+ and then Mg2+) as 
most effective in stabilizing the engaged conformation of the dynamic loop against AMP- 
and Fru-2,6-P2- induced conformational change (56).  In the model of the preceding 
paragraph, Fru-2,6-P2 inhibition, AMP inhibition, and AMP/Fru-2,6-P2 synergy depend upon 
the dissociation of the catalytic loop from the active site, and a quaternary transition out of 
the R-state.  Mn2+ is most effective in stabilizing the engaged conformation of the dynamic  
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FIGURE FOUR.  Stereo-view of correlated movements in Glu98 and Asp74 that sterically prohibit 
the engaged loop.   Selected residues of the active site of the porcine Fru-2,6-P2•Mg2+ structure 
(heavy lines) and R-state enzyme (light lines) are shown.  Asp74 forms a critical hydrogen bond 
(broken line) with the amide N of Lys71 in the R-state which stabilizes the engaged loop.  The 
displacement of Asp74 by Glu98 disrupts this interaction and positions the Asp74 side-chain to 
sterically block the engaged conformation of the loop.  Rotation about the Ψ angle of Lys71 puts the 
loop in a disengaged conformation which prevents what would be bad contacts between Asp74 and 
Lys71. This drawing was prepared with XTALVIEW (54). 
 
 
 
 133 
   
 
loop (56), and requires the highest concentrations of AMP and Fru-2,6-P2 in order to observe 
inhibition and synergism (32). 
Unlike porcine FBPase, the E. coli enzyme exhibits no AMP/Fru-2,6-P2 synergism 
(FIGURE ONE) despite being potently inhibited by both ligands individually (42).  Applying 
the model that accounts for the behavior of the porcine enzyme, we must conclude AMP 
and/or Fru-2,6-P2 cannot cause a quaternary transition that destabilizes metal binding and an 
engaged dynamic loop.  Indeed, whereas AMP (perhaps along with Glc-6-P) causes a 
quaternary transition out of the R-state (43), Fru-2,6-P2-bound E. coli FBPase remains in the 
R-state with a dynamic loop in a conformation similar to the engaged conformation of R-
state porcine FBPase.  Whereas AMP and allosteric activators are antagonists in the E. coli 
system, PEP and citrate enhance Fru-2,6-P2 inhibition, decreasing the Ki coincidently with 
the Km for the substrate in enzyme incubated assays (38); a finding consistent with the co-
ligation of citrate and Fru-2,6-P2 in the crystal structure reported here. 
The single-celled eukaryote Saccharomyces cerevisiae produces Fru-2,6-P2 within 
one minute of its exposure to exogenous glucose (67).  FBPase from this organism exhibits 
Fru-2,6-P2/AMP synergy (68), but lacks the PEP/citrate activator site of the bacterial enzyme 
(20, 38).  Moreover, Fru-2,6-P2 allosterically activates PFK of S. cerevisiae, whereas E. coli 
PFK lacks the allosteric site for Fru-2,6-P2 (69).  We see then from an evolutionary 
perspective a significant divide between eukaryotes and bacteria, but the one trait common to 
organisms which do or do not produce Fru-2,6-P2 is the inhibition of FBPase.  Hence, at 
some point in evolution, Fru-2,6-P2 probably existed as an inhibitor of FBPase before it 
became an allosteric activator of PFK (33, 41) 
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FBPase figures prominently in strategies to treat diabetes mellitus.  The implication 
that hyper-activity in gluconeogenesis is a cause of diabetic hyperglycemia (70) has made 
mammalian FBPase a target for the development of anti-diabetic drugs (44, 71, 72).  Several 
novel inhibitors have been developed (44, 71), and detailed knowledge of the structural 
mechanism of AMP inhibition has resulted in the rational design of a potential drug that 
targets the AMP site (72).  This FBPase-specific inhibitor alleviates diabetic hyperglycemia 
in rats, providing a proof-of-principle for the use of FBPase inhibitors in diabetes therapy 
(73).  Our investigation into the mechanism of Fru-2,6-P2 inhibition reveal changes induced 
by the binding of Fru-2,6-P2 which may aide in the development of a rational drug which is 
synergistic with AMP and Fru-2,6-P2.  The efficacy of such a drug would be enhanced 
dramatically by synergistic effects of AMP and Fru-2,6-P2. 
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CHAPTER VI.  GENERAL CONCLUSIONS AND FUTURE RESEARCH 
General Conclusions 
It has now been demonstrated that E. coli FBPase is activated by intermediates of the 
glycolytic pathway (PEP) and the TCA cycle (citrate) while being inhibited by AMP and 
Glc-6-P.  These effectors have elaborate relationships (antagonism/synergism) that arise from 
the structural flexibility of the FBPase tetramer, which can adopt several quaternary states (a 
property conserved in the mammalian enzyme).  Further, it has been demonstrated that the 
bacterium E. coli is but one member of a larger group of heterotrophic bacteria which retain 
the metabolic flexibility to utilize carbon sources which enter central carbohydrate 
metabolism both above and below the FBPase/PFK step, and hence would benefit from rapid 
effector-based regulation of FBPase.  This new perspective on FBPase in bacteria is 
profoundly different from the previous view that bacterial FBPases were pedestrian, merely 
responding to modest changes in AMP levels.  Through the combined effects of PEP, citrate, 
AMP, and Glc-6-P (and perhaps others) FBPase is capable of functioning as a metabolic 
sensor, altering the glycolytic/gluconeogenic flux to favor anabolic synthesis of pentose and 
hexose sugars for growth when only smaller carbon substrates are available.  Implications 
include a necessary revision of models which seek to predict metabolic states or flux in 
silico.  Our findings might bring a skeptic to question the validity of such approaches, given 
the demonstrated gap in knowledge regarding FBPase, a central regulatory enzyme, in E. 
coli, the world’s best understood organism.  Other mechanisms of regulation in central 
metabolism may yet be undiscovered in this bacterium, rendering an accurate prediction 
doubtful, based on current knowledge.  
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 The structural mechanism of AMP/PEP antagonism in E. coli FBPase may be the best 
understood example of an activator which induces a conformational change from a distinct 
allosteric site to block an inhibition site utilizing primarily a single amino acid side-chain.  
Movements in helices in response to PEP or AMP ligation demonstrate how a protein 
scaffold can function as a series of simple machines (rods, levers, planes) to change 
conformation and alter enzyme activity.  Additionally, the overall structural similarity 
between the bacterial and mammalian enzymes provides an excellent example of how an 
identical protein scaffold can be altered to adopt novel functionalities like the distinct 
regulatory sites and mechanisms of bacterial and mammalian FBPases.   
 The conservation of FBPase in living organisms, coupled with the conservation of the 
effector binding sites for PEP, Glc-6-P, and AMP (all allosteric sites), implies a high degree 
of necessity for regulation.  Considering the detailed structural information available and the 
specific conservation in prokaryotes, it seems logical that FBPase might be a target for 
antimicrobial research.  A potential drug developed for either the PEP or Glc-6-P site would 
not only be innocuous to humans, livestock, and crops, but would also have no effect on a 
host of organisms which inhabit the human body, the organisms referred to as ‘good 
bacteria’.   Many of these organisms which colonize the human digestive tract, for example, 
are saccharolytic obligate fermenters, which have no need for such regulation in FBPase, and 
hence the use of an FBPase-specific drug would not cause some of the undesirable side-
effects of a general antibiotic.  The major question which surrounds such a pursuit involves 
the efficacy of such a drug in reducing pathogenicity, a topic which will be discussed further 
in the future research section below.   
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 Finally, observations in Chapter V have demonstrated for the first time that both 
AMP and Fru-2,6-P2 induce quaternary state changes in mammalian FBPase, putting to rest 
25 years of speculation regarding this matter.  This finding also explains the numerous 
observations of previous investigators which suggest that Fru-2,6-P2 is an allosteric inhibitor, 
despite evidence that it binds to the active site.  The first Fru-2,6-P2 bound FBPase structure 
silenced speculation about the locus of binding, but further confounded the explanation for 
apparent allosteric effects.  The reason for the difficulty in resolving this conundrum is now 
clear: Fru-2,6-P2 binds to the active site and acts as both a competitive inhibitor and affects a 
quaternary change.  The definition of Fru-2,6-P2 as an allosteric inhibitor arises from its 
effects being felt at a distant sites, these being the AMP pocket, some 28Å away, and perhaps 
active sites from adjacent subunits, which may be altered due to the transition to the IT-state.    
The quaternary changes induced by both AMP and Fru-2,6-P2 can also account for 
the synergy between physiological inhibitors, which is thought to both increase inhibitor 
potency (Fru-2,6-P2 leverages its effect by enhancing AMP inhibition) and also serve as a 
fine-tuning mechanism for FBPase activity.  Knowledge of the physiological mechanisms of 
inhibition may aid the development of Type 2 diabetes mellitus drugs which inhibit FBPase, 
in addition to enriching to the current knowledge of human carbohydrate and energy 
metabolism.   
    
Future Research with Mammalian and Bacterial FBPase 
 Several questions remain with regard to the regulation of E. coli  FBPase by effectors.  
In Chapter III, the potential for another effector, which might bind the C1-C2 interface was 
suggested, while in Chapter IV, it was suggested that yet another ligand may bind to the C1-
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C4 interface and stabilize the T-like state.  Further studies could investigate the potential for 
other effectors of FBPase which may bind with Glc-6-P and/or AMP to stabilize the inhibited 
state.  It is not possible to completely distinguish between the individual effects of AMP and 
Glc-6-P with the current set of available structures.  To this end, further efforts to crystallize 
the enzyme in the presence of only one inhibitor might benefit from the isolation of 
polyhistidine-tagged enzyme which lacks the phosphoglucose isomerase impurity which 
produces Glc-6-P from Fru-6-P in the crystallization droplet.  Additionally, analysis of 
ligands that bind and stabilize the C1-C4 interface may aid in crystallization of T-like 
structures by further rigidifying the inhibitor-bound structure.   
 The potential for E. coli FBPase as an antibiotic target rests on the identification and 
characterization of a suitable target organism.  Do pathogens require active FBPase for 
survival and pathogenesis?  The answers are unclear.  For E. coli, requirement for FBPase is 
nutrient dependent, and so lethality would depend on the pathogen’s environment in the 
body.  The recent finding that Leishmania major requires FBPase for growth within its host 
is both surprising and encouraging.  Of course, there is no necessity for a drug to impose 
absolute lethality upon bacterial FBPase inactivation.  An effective antibiotic need only slow 
the growth of an organism to allow the host immune defenses to clear the infection.  
Therefore the appropriate indicator is not growth on culture plates, but pathogenicity in an 
animal system.  The ‘acid test’ for such an investigation would be to create FBPase knock-
out strains of potential target organisms and determine the effect of the gene deletion on 
pathogenicity in animal models.  If the results are promising, then rational design of 
compounds which target either the PEP/citrate site or the Glc-6-P site may result in novel 
bacterial FBPase specific inhibitors with antibiotic potential.   
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 Chapter V presents new structural evidence regarding Fru-2,6-P2 inhibition of 
mammalian FBPase.  Mutational analysis of key residues which differ between E. coli and 
porcine FBPases may either confirm or deny proposed models for the allosteric mechanism.  
To date, no single mutation, or set of mutations, has been successful in eliminating 
AMP/Fru-2,6-P2 synergism while leaving the potent individual inhibition by both compounds 
intact.  Examination of individual residues implicated in the mechanism described in Chapter 
V may finally resolve the matter.  Finally, the wealth of structural information regarding the 
response of FBPase (bacterial and mammalian) to ligation by numerous effectors may now 
allow the rational design of new antidiabetic drugs which target FBPase.  Investigations of 
this nature are now beginning in our laboratory, based largely on the structural and kinetic 
data presented here.   
 
 
 
